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[57) ABSTRACT 
A novel class of peptide a-ketoamides useful for selectively 
inhibiting serine proteases, selectively inhibiting cysteine 
proteases, generally inhibiting all serine proteases, and gen-
erally inhibiting all cysteine proteases, having the formula 
M1-AA-NH-CHR2-CO-CO-NR3R4, M1-AA2-AA1-
CO-NR3R4, M1-AA-AA-AA-CO-NR3R4, M1-AA-AA-
AA-AA-CO-NR3R4, or M1-AA-CO-NR3R4. 
5 Claims, No Drawings 
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PEPTIDES KETOAMIDES 
This is a continuation of application Ser. No. 08/247,081 
filed on May 20, 1994, now abandoned, which is a continu-
ation of Ser. No. 08/118,997 filed on Sep. 9, 1993, now 5 
abandoned, which is a continuation of Ser. No. 07/815,073 
filed on Dec. 27, 1991, now abandoned. 
2 
OH would be designated Z-Leu-Phe-CO-NH-Et which 
represents C6H5CH20CO-NH-CH(CH2CH(CH2)-
CO-NH-CH(CH2Ph)-CO-CO-NH-Et. 
3. Description of the Related Art 
Cysteine Proteases. Cysteine proteases such as calpain 
use a cysteine residue in their catalytic mechanism in 
contrast to serine proteases which utilize a serine residue. 
Cysteine proteases include papain, cathepsin B, calpains, 
and several viral enzymes. Neural tissues, including brain, 
BACKGROUND OF THE INVENTION 10 are known to possess a large variety of proteases, including 
1. Field of the Invention at least two calcium stimulated proteases termed calpains. 
Calpains are present in many tissues in addition to the brain. 
This invention relates to a novel class of peptide ketoa- Calpain I is activated by micromolar concentrations of 
mides useful for selectively inhibiting serine proteases, calcium while calpain II is activated by millimolar concen-
selectively inhibiting cysteine proteases, generally inhibit-
15 
trations. In the brain, calpain II is the predominant form, but 
ing all serine proteases, and generally inhibiting all cysteine cal pain I is found at synaptic endings and is thought to be the 
proteases. Serine proteases and cysteine proteases are form involved in long term potentiation, synaptic plasticity, 
involved in numerous disease states and inhibitors for these and cell death. Other Ca2+ activated cysteine proteases may 
enzymes can be used therapeutically for the treatment of exist, and the term "calpain" is used to refer to all Ca2+ 
diseases involving serine proteases or cysteine proteases. We 
20 
activated cysteine proteases, including calpain I and calpain 
have discovered that peptide a-ketoamides can be con- II. The terms "calpain I" and "calpain II" are used herein to 
structed to inhibit selectively individual serine or cysteine refer to the micromolar and millimolar activated calpains, 
proteases or groups of serine or cysteine proteases. We have respectively, as described above. While calpains degrade a 
found that peptide ketoamides which contain hydrophobic wide variety of protein substrates, cytoskeletal proteins 
aromatic amino acid residues in the P 1 site are potent 25 seem to be particularly susceptible to attack. In some cases, inhibitors of chymases and chymotrypsin-like enzymes. the products of the proteolytic digestion of these proteins by 
Ketoamides containing small hydrophobic amino acid resi- calpain are distinctive and persistent over time. Since 
dues at the P 1 position are good inhibitors of elastases. cytoskeletal proteins are major components of certain types 
Inhibitors of elastases and chymases are useful as anti- of cells, this provides a simple method of detecting calpain 
inflammatory agents. We show that peptide ketoamides 
30 
activity in cells and tissues. Thus, calpain activation can be 
which contain cationic amino acid residues such as Arg and measured indirectly by assaying the proteolysis of the 
Lys in the P 1 site will be potent inhibitors of trypsin and cytoskeletal protein spectrin, which produces a large, dis-
blood coagulation enzymes. These inhibitors are thus useful tinctive and biologically persistent breakdown product when 
as anticoagulants. Cysteine proteases such as papain, cathe- attacked by calpain [Siman, Baudry, and Lynch, Proc. Natl. 
psin B, and calpain I and II are also inhibited by ketoamides. 
35 
Acad. Sci. USA 81, 3572-3576 (1984); incorporated herein 
Ketoamides with aromatic amino acid residues in the P 1 site by reference]. Activation of cal pains and/or accumulation of 
are good inhibitors for cathepsin B and papain. Thus, they breakdown products of cytoskeletal elements has been 
would have utility as anticancer agents. Ketoamides with observed in neural tissues of mammals exposed to a wide 
either aromatic amino acid residues or small hydrophobic variety of neurodegenerative diseases and conditions. For 
alkyl amino acid residues at P 1 are good inhibitors of calpain 40 example, these phenomena have been observed following I and II. These inhibitors are useful as neuroprotectants and ischemia in gerbils and rats, following stroke in humans, 
can be used as therapeutics for the treatment of neurode- following administration of the toxins kainate, trimethyltin 
generation and stroke. or colchicine in rats, and in human Alzheimer's disease. 
2. Nomenclature Several inhibitors of calpain have been described includ-
In discussing the interactions of peptides with serine and 45 ing peptide aldehydes such as Ac-Leu-Leu-Nle-H and Ieu-
cysteine proteases, we have utilized the nomenclature of peptin (Ac-Leu-Leu-Arg-H), as well as epoxysuccinates 
Schechter and Berger [Biochem. Biophys. Res. Commun. such as E-64. These compounds are not especially useful at 
27, 157-162 (1967); incorporated herein by reference]. The inhibiting calpain in neural tissue in vivo because they are 
individual amino acid residues of a substrate or inhibitor are poorly membrane permeant and, accordingly, are not likely 
designated P 1, P 2 , etc. and the corresponding subsites of the 50 to cross the blood brain barrier very well. Also, many of 
enzyme are designated S1, S2, etc. The scissile bond of the these inhibitors have poor specificity and will inhibit a wide 
substrate is S1-S1'. The primary substrate recognition site variety of proteases in addition to calpain. Other classes of 
of serine proteases is S1• The most important recognition compounds which inhibit cysteine proteases include peptide 
subsites of cysteine proteases are S1 and S2• diazomethyl ketone [Rich, D. H., in Protease Inhibitors, 
Amino acid residues and blocking groups are designated 55 Barrett A. J., and Salversen, G., Eds., Elsevier, New York, 
using standard abbreviations [see J. Biol. Chem. 260, 14-42 1986, pp 153-178; incorporated herein by reference). Pep-
(1985) for nomenclature rules; incorporated herein by ref- tide diazomethyl ketones are potentially carcinogenic and 
erence]. An amino acid residue (AA) in a peptide or inhibitor are thought to be poorly membrane permeant and to have 
structure refers to the part structure -NH-CHR1-CO-, low specificity. Thus, no effective therapy has yet been 
where R1 is the side chain of the amino acid residue AA. A 60 developed for most neurodegenerative diseases and condi-
peptide a-ketoester residue would be designated -AA-CO- tions. Millions of individuals suffer from neurodegenerative 
OR which represents the part structure -NH-CHR1- diseases and thus, there is a need for therapies effective in 
CO-CO-OR. Thus, the ethyl ketoester derived from treating and preventing these diseases and conditions. 
benzoyl alanine would be designated Bz-Ala-CO-OEt which Cathepsin B is involved in muscular dystrophy, myocar-
represents C6H5CO-NH-CHMe-CO-CO-OEt. Pep- 65 dial tissue damage, tumor metastasis, and bone resorption. 
tide ketoamide residues would be designated -AA-CO- In addition, a number of viral processing enzymes, which 
NH-R. Thus, the ethyl keto amide derived from Z-Leu-Phe- are essential for viral infection, are cysteine proteases. 
5,610,297 
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Inhibitors of cysteine proteases would have multiple thera-
peutic uses. 
Serine Proteases. Serine proteases play critical roles in 
several physiological processes such as digestion, blood 
coagulation, complement activation, fibrinolysis, viral infec- 5 
tion, fertilization, and reproduction. Serine proteases are not 
only a physiological necessity, but also a potential hazard if 
they are not controlled. Uncontrolled proteolysis by 
elastases may cause pancreatitis, emphysema, rheumatoid 
arthritis, bronchial inflammation and adult respiratory dis- 10 
tress syndrome. It has been suggested that a new trypsin-like 
cellular enzyme (tryptase) is involved in the infection of 
human immunodeficiency virus typ·e 1 [HIV-I; Hattori et al., 
FEBS Letters 248, pp. 48-52 (1989)], which is a causative 
agent of acquired immunodeficiency syndrome (AIDS). 
P ~ Jasmin is involved in tumor invasiveness, tissue remodel-
ing, blistering, and clot dissociation. Accordingly, specific 
and selective inhibitors of these proteases should be potent 
anticoagulants, anti-inflammatory agents, anti-tumor agents 
and anti-viral agents useful in the treatment of protease- 20 
related diseases [Powers and Harper, Proteinase Inhibitors, 
pp 55-152, Barrett and Salvesen, eds., Elsevier, (1986); 
incorporated herein by reference]. In vitro proteolysis by 
chymotrypsin, trypsin or the elastase family is a serious 
. problem in the production, purification, isolation, transport 25 
or storage of peptides and proteins. 
Elastase inhibitors are anti-inflammatory agents which 
can be used to treat elastase-associated inflammation includ-
ing rheumatoid arthritis and emphysema. Although the natu-
rally occurring protease inhibitor, al-protease inhibitor (o:l- 30 
Pl) has been used to treat patients with emphysema, this 
protein inhibitor is not widely used clinically due to the high 
dosage needed for treatment and the difficulty of producing 
large quantifies. Therefore, small molecular weight elastase 
inhibitors are needed for therapy. Other low molecular 35 
weight elastase inhibitors have utility for the treatment of 
emphysema and intimation (see: 1-carpapenem-3-carboxy-
lic esters as anti-inflammatory agents, U.S. Pat. No. 4,493, 
839; N-carboxyl-thienamycin esters and analogs thereof as 
anti-inflammatory agents, U.S. Pat. No. 4,495,197; incorpo- 40 
rated herein by reference). 
45 
4 
coagulation are useful anticoagulants in vivo [see for 
example: H-D-Phe-Pro-Arg-CH2C1, Hanson and Harker, 
Proc. Natl. Acad. Sci. 85, 3184-3188 (1988); 7-Amino-4-
chloro-3-(3-isothiureidopropoxy)isocoumarin (ACITIC), 
Oweida, Ku, Luresden, Karo, and Powers, Thrombos. Res. 
58, 191-197 (1990); incorporated herein by reference]. 
Ketoesters. A few amino acid and peptide ketoesters and 
ketoacids have been previously reported. Cornforth and 
Cornforth [J. Chem. Soc., 93-96 (1953); incorporated herein 
by reference] report the synthesis of the ketoacids 
PhCH2CO-Gly-CO-OH and Ac-Gly-CO-OH upon 
hydrolysis of heterocyclic molecules. Charles et al. [J. 
Chem. Soc. Perkin I, 1139-1146 (1980); incorporated herein 
by reference] use ketoesters for the synthesis of bicyclic 
heterocycles. They report the synthesis ofn-BuCO-Ala-CO-
OEt, PrCO-Ala-CO-OEt, cyclopentylCO-Ala-CO-OEt, 
PrCO-PhGly-CO-OEt, and Bz-Ala-CO-OEt. Hori et al. 
[Peptides: Structure and Function-Proceedings of the Ninth 
American Peptide Symposium (Deber, Hruby, and Kopple, 
Eds.) Pierce Chemical Co., pp 819-822 (1985); incorporated 
herein by reference] report Bz-Ala-CO-OEt, Bz-Ala-CO-
OH, Z-Ala-Ala-Abu-CO-OEt, Z-Ala-Ala-Abu-CO-OBzl, 
and Z-Ala-Ala-Ala-Ala-CO-OEt (Abu=2-aminobulanoic 
acid or aminobutyric acid) and report that these compounds 
inhibit elastase. Trainer [Trends Pharm. Sci. 8, 303-307 
(1987); incorporated herein by reference] comments on one 
of this compounds. Burkhart, J., Peet, N. P., and Bey, P. 
[Tetrahedron Lett. 29, 3433-3436 (1988); incorporated 
herein by reference] report the synthesis of Z-Val-Phe-CO-
OMe and Bz-Phe-CO-OMe. 
Mehdi et al., [Biochem. Biophys. Res. Comm. 166, 
595-600 (1990); incorporated herein by reference] report 
the inhibition of human neutrophil elastase and cathepsin G 
by peptide o:-ketoesters. Angelastro et al., [J. Med. Chem. 
33, 13-16 (1990); incorporated herein by reference] report 
some o:-ketoesters which are inhibitors of calpain and chy-
motrypsin. Hu and Abeles [Arch. Biochem. Biophys. 281, 
271-274 (1990)]; incorporated herein by reference] report 
some peptidyl o:-ketoamides and o:-ketoacids which are 
inhibitors of cathepsin B and papain. Peet et al. [J. Med. 
Chem. 33, 394-407 (1990); incorporated herein by refer-
ence] report some peptidyl o:-ketoesters which are inhibitors 
of porcine pancreatic elastase, human neutrophil elastase, 
and rat & human neutrophil cathepsin G. 
Ketoamides. A single peptide ketoamide is reported in the 
literature by Hu and Abeles [Arch. Biochem. Biophys. 281, 
271-274 (1990)]. This compound Z-Phe-NHCH2CO-
CO-NH-Et or Z-Phe-Gly-CO-NH-Et is reported to be an 
Anticoagulants and antithrombotic drugs are used in a 
variety of thrombotic disorders. The 1990 Physician's Desk 
Reference lists several anticoagulant drugs (heparin, prota-
mine sulfate and warfarin), a few antiplatelet drugs (aspirin) 
and several thrombolytic agents. Heparin and warfarin are 
commonly used clinically for prevention and treatment of 
venous thrombosis and pulmonary embolism. Heparin 
inhibits the blood coagulation activity by accelerating the 
binding of natural plasma protease inhibitor antithrombin III 
with coagulation factors, and warfarin acts as a vitamin K 
antagonist and inhibits the synthesis of coagulation factors. 
None of the anticoagulant drugs, antithrombotic drugs, 
fibrinolytic agents and antiplatelet drugs are highly effective 
50 inhibitor of papain (K;=l .5 µM) and cathepsin B (K;=4 µM). 
in all clinical situations and many induce side reactions [Von 55 
Kaulla, Burger's Medicinal Chemistry, Part II, pp 
1081-1132, Wolff, ed., (1979); incorporated herein by ref-
erence]. Coagulation disorders such as disseminated intra-
vascular coagulation, bleeding complications of medical and 
surgical procedures and bleeding complications of systemic 60 
illness are still difficult to manage [Ingram, Brozovic and 
Slater, Bleeding Disorders, pp 1-413, Blackwell Scientific 
Publications, (1982); incorporated herein by reference]. In 
the treatment of patients with coagulation problems, antico-
agulant or antithrombotic agents of diverse mechanisms are 65 
urgently sought in order to provide better medical care. 
Inhibitors for the trypsin-like enzymes involved in blood 
SUMMARY OF THE INVENTION 
We have discovered that peptide and amino acid cc-
ketoamide derivatives are a novel group of inhibitors for 
serine proteases and cysteine proteases. Inhibitors are com-
pounds that reduce or eliminate the catalytic activity of the 
enzyme. We have discovered that peptide o:-ketoamide 
derivatives, which have an amino acid sequence similar to 
that of good substrates for a particular protease, are good 
inhibitors for that protease. Thus, we are able to predict the 
structures of new inhibitors for other serine and cysteine 
proteases based on knowledge of their substrate specificities. 
We have discovered some peptide o:-ketoamide deriva-
tives which are specific inhibitors for chymotrypsin. Chy-
motrypsin and chymotrypsin-like enzymes hydrolyze pep-
tide bonds where P 1 amino acid is Trp, Tyr, Phe, Met, Leu 
5,610,297 
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or other amino acid residues which contain aromatic or large 
alkyl side chains. Inhibitors with these residues at P 1 are 
good chymotrypsin and chymase inhibitors. Trypsin and 
trypsin-like enzymes normally cleave peptide bonds in pro-
teins and peptides where the amino acid residue on the 5 
carbonyl side of the split bond (P 1 residue) is Lys or Arg. We 
show that peptide a-ketoamide derivatives which have Lys 
or Arg at P 1 will be good inhibitors for these enzymes. 
Elastase and elastase-like enzymes cleave peptide bonds 
where the P 1 amino acid is Ala, Val, Ser, Leu and other 10 
similar amino acids. We shown that inhibitors with these 
residues at P 1 are good elastase inhibitors. All of the above 
enzymes have extensive secondary specificity and recognize 
amino acid residues removed from the P 1 residue. 
The peptide a-ketoamide derivatives are also novel and 15 
potent inhibitors of cysteine proteases including calpains 
and cathepsin B. The calpain inhibitors are useful for 
treatment of various neurodegenerative diseases and condi-
tions, including ischemia, stroke, and Alzheimer's disease. 
The new protease inhibitors, especially the elastase 20 
inhibitors, trypsin inhibitors, and chymase inhibitors are 
useful for controlling tissue damage and various inflamma-
tory conditions mediated by proteases such as blistering. The 
inhibitors for blood coagulation enzymes will be useful 
anticoagulants and could be used to treat thrombosis. 25 
The peptide and amino acid a-ketoamide derivatives are 
also useful in vitro for inhibiting trypsin, elastase, chymot-
rypsin and other serine proteases of similar specificity, and 
for inhibiting serine proteases in general. The inhibitors can 30 be used to identify new proteolytic enzymes encountered in 
research. They can also be used in research and industrially 
to prevent undesired proteolysis that occurs during the 
production, isolation, purification, transport and storage of 
valuable peptides and proteins. Such proteolysis often 35 destroys or alters the activity and/or function of the peptides 
and proteins. Uses would include the addition of the inhibi-
tors to antibodies, enzymes, plasma proteins, tissue extracts 
or other proteins and peptides which are widely sold for use 
in clinical analyses, biomedical research, and for many other 40 
reasons. For some uses a specific inhibitor would be desir-
able, while in other cases, an inhibitor with general speci-
ficity would be preferred. 
6 
occurs in the process of production, isolation, purification, 
storage or transport of peptides and proteins. These inhibi-
tors may be useful as therapeutic agents for treatment of 
neurodegeneration, viral infections, muscular dystrophy, 
myocardial tissue damage, tumor metastasis, and bone 
resorption. 
The novel class of dipeptide a-ketoamides have the 
following structural formula: 
M 1-AA-NH-CHR2-CO-CO-NR3R4 
or a pharmaceutically acceptable salt, wherein 
M1 represents H, NH2-CO-, NH2-CS-, NH2-
S02-, X-NH-CO-, X2N-CO-, X-NH-CS-, 
X2N-CS-, X-NH-S02-, X2N-S02-, X-CO-, 
X-CS-, X-S02-, X-0-CO-, or X-0-CS-; 
X is selected from the group consisting of C1_10 alkyl, 
cl-10 fiuoroalkyl, cl-10 alkyl substituted with J, cl-10 
ftuoroalkyl substituted with J, 1-admantyl, 9-ftuorenyl, phe-
nyl, phenyl substituted with K, phenyl disubstituted with K, 
phenyl trisubstituted with K, naphthyl, naphthyl substituted 
with K, naphthyl disubstituted with K, naphthyl trisubsti-
tuted with K, C1_10 alkyl with an attached phenyl group, 
cl-10 alkyl with two attached phenyl groups, cl-10 alkyl 
with an attached phenyl group substituted with K, C 1_ 10 
alkyl with two attached phenyl groups substituted with K, 
cl-10 alkyl with an attached phenoxy group, and cl-10 alkyl 
with an attached phenoxy group substituted with K on the 
phenoxy group; 
J is selected from the group consisting ofhalogen, COOH, 
OH, CN, N02, NH2, C1_10 alkoxy, C1_10 alkylamine, C2_12 
dialkylamine, C1_10 alkyl-0-CO-, C1_ 10 alkyl-0-CO-
NH-, and C1_ 10 alkyl-S-; 
K is selected from the group consisting of halogen, C1_ 10 
alkyl, C1_10 perfiuoroalkyl, C1_10 alkoxy, N02, CN, OH, 
C02H, amino, C1_10 alkylamino, C2_12 dialkylamino, C1C10 
acyl, and C1_ 10 alkoxy-CO-, and C1_ 10 alkyl-S-; 
AA is a side chain blocked or unblocked amino acid with 
the L configuration, D configuration, or no chirality at the 
a-carbon selected from the group consisting of alanine, 
valine, leucine, isoleucine, proline, methionine, methionine 
sulfoxide, phenylalanine, tryptophan, glycine, serine, threo-
nine, cysteine, tyrosine, asparagine, glutarnine, aspartic acid, 
glutamic acid, lysine, arginine, histidine, phenylglycine, 
beta-alanine, norleucine, norvaline, alpha-aminobutyric 
DETAILED DESCRIPTION OF THE 
INVENTION 
Peptide a-ketoamides are transition state analog inhibi-
tors for serine proteases and cysteine proteases. Peptide 
a-ketoamides containing hydrophobic amino acid residues 
in the P 1 site have been found to be excellent inhibitors of 
serine proteases including porcine pancreatic elastase and 
bovine chymotrypsin. We show that peptide a-ketoamides 
containing amino acid residues with cationic side chains in 
the P 1 site will be excellent inhibitors of several serine 
proteases including bovine trypsin, bovine thrombin, human 
plasma kallikrein, porcine pancreatic kallikrein, human fac-
45 acid, epsilon-aminocaproic acid, citrulline, hydroxyproline, 
ornithine, homoarginine, sarcosine, indoline 2-carboxylic 
acid, 2-azetidinecarboxylic acid, pipecolinic acid (2-piperi-
dine carboxylic acid), 0-methylserine, 0-ethylserine, S-me-
thylcysteine, S-ethylcysteine, S-benzylcysteine, NH2-
tor Xla and human plasmin. Peptide a-ketoamides contain-
ing amino acid residues with hydrophobic side chain at the 
50 CH(CH2CHE~)-COOH, alpha-aminoheptanoic acid, 
NH2-CH(CH2-l-napthyl)-COOH, NH2-CH(CH2-2-
napthyl)-COOH, NH2-CH(CH2-cyclohexyl)-COOH, 
NH2-CH(CH2-cyclopentyl)-COOH, NH2-CH(CH2-cy-
clobutyl)-COOH, NH2-CH(CHrcyclopropyl)-COOH, tri-
55 fiuoroleucine, and hexafiuoroleucine; 
R2 is selected from the group consisting of C1_8 branched 
and unbranched alkyl, cl-8 branched and unbranched 
cyclized alkyl, and cl-8 branched and unbranched fiuoro-
alkyl; 
R3 and R4 are selected independently from the group 
consisting of H, C1_ 20 alkyl, C3_20 cyclized alkyl, C1_20 
alkyl with a phenyl group attached to the cl-20 alkyl, c3-20 
cyclized alkyl with an attached phenyl group, cl-20 alkyl 
with an attached phenyl group substituted with K, C1_20 
P 1 site have also been found to be excellent inhibitors of 60 
several cysteine proteases including papain, cathepsin B, 
calpain I, and calpain II. These structures may be used in 
vivo to treat diseases such as emphysema, adult respiratory 
distress syndrome, rheumatoid arthritis and pancreatitis 
which result from uncontrolled proteolysis by elastase, 
chymotrypsin, trypsin and related serine proteases. These 
inhibitors may be used in vitro to prevent proteolysis which 
65 alkyl with an attached phenyl group disubstituted with K, 
cl-20 alkyl with an attached phenyl group trisubstituted with 
K, C3_20 cyclized alkyl with an attached phenyl group 
5,610,297 
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beta-alanine, norleucine, norvaline, alpha-aminobutyric 
acid, epsilon-aminocaproic acid, citrulline, hydroxyproline, 
omithine, homoarginine, sarcosine, indoline 2-carboxylic 
acid, 2-azetidinecarboxylic acid, pipecolinic acid (2-piperi-
substituted with K, C1_10 alkyl with a morpholine 
[-N(CH2CH2)0] ring attached through nitrogen to the 
alkyl, cl-10 alkyl with a piperidine ring attached through 
nitrogen to the alkyl, cl-10 alkyl with a pyrrolidine ring 
attached through nitrogen to the alkyl, cl-20 alkyl with an 
OH group attached to the alkyl, -CH2CH20CH2CH20H, 
cl-10 with an attached 4-pyridyl group, cl-10 with an 
attached 3-pyridyl group, cl-10 with an attached 2-pyridyl 
group, C1_10 with an attached cyclohexyl group, -NH-
CH2CH2-(4-hydroxyphenyl), and -NH-CH2CHz-(3-in-
dolyl). 
5 dine carboxylic acid), 0-methylserine, 0-ethylserine, S-me-
thylcysteine, S-ethylcysteine, S-benzylcysteine, NH2-
CH(CH2CHEt2)-COOH, alpha-aminoheptanoic acid, 
NH2-CH(CHr 1-napthyl)-COOH, NH2-CH(CH2-2-
napthyl)-COOH, NH2-CH(CH2-cyclohexyl)-COOH, 
The novel class of dipeptide a-ketoamides also have the 
following structural formula: 
10 
NH2-CH(CH2-cyclopentyl)-COOH, NH2-CH(CH2-cy-
clobutyl)-COOH, NH2-CH(CHz-cyclopropyl)-COOH, tri-
fluoroleucine, and hexafluoroleucine; 
M 1-AA2-AA1-CO-NR3R4 
or a pharmaceutically acceptable salt, wherein 
M1 represents H, NH2-CO-, NH2-CS-, NH2-
S02-, X-NH-CO-, X2N-CO-, X-NH-CS-, 
X2N-CS-, X-NH-S02, X2N-S02-, X-CO-, 
X-CS-, X-S02-, X-0-CO-, or X-0-CS-; 
R3 and R4 are selected independently from the group 
consisting of H, C1_20 alkyl, C3_20 cyclized alkyl, C1_20 
alkyl with a phenyl group attached to the cl-20 alkyl, c3-20 
15 
cyclized alkyl with an attached phenyl group, cl-20 alkyl 
with an attached phenyl group substituted with K, C1_20 
alkyl with an attached phenyl group disubstituted with K, 
cl-20 alkyl with an attached phenyl group trisubstituted with 
K, C3_20 cyclized alkyl with an attached phenyl group 20 substituted with K, C1_10 alkyl with a morpholine 
[-N(CH2CH2)0] ring attached through nitrogen to the 
alkyl, cl-10 alkyl with a piperidine ring attached through 
nitrogen to the alkyl, cl-10 alkyl with a pyrrolidine ring 
attached through nitrogen to the alkyl, cl-20 alkyl with an 
X is selected from the group consisting of C1_10 alkyl, 
cl-10 fluoroalkyl, cl-10 alkyl substituted with J, cl-10 
fluoroalkyl substituted with J, 1-admantyl, 9-fluorenyl, phe-
nyl, phenyl substituted with K, phenyl disubstituted with K, 
phenyl trisubstituted with K, naphthyl, naphthyl substituted 
with K, naphthyl disubstituted with K, naphthyl trisubsti-
tuted with K, C1_10 alkyl with an attached phenyl group, 
cl-10 alkyl with two attached phenyl groups, cl-10 alkyl 
with an attached phenyl group substituted with K, C1_10 
alkyl with two attached phenyl groups substituted with K, 
cl-10 alkyl with in attached phenoxy group, and cl-10 alkyl 
with an attached phenoxy group substituted with K on the 
phenoxy group; 
25 OH group attached to the alkyl, -CH2CH20CH2CH20H, 
cl-10 with a attached 4-pyridyl group, cl-10 with an 
attached 3-pyridyl group, cl-10 with an attached 2-pyridyl 
group, C1_10 with an attached cyclohexyl group, -NH-
CH2CH2-(4-hydroxyphenyl), and -NH-CH2CH2-(3-in-
3o dolyl). 
J is selected from the group consisting of halogen, COOH, 
OH, CN, N02, N02, C1_10 alkoxy, C1_10 alkylamine, C2_12 35 
dialkylamine, C1_10 alkyl-0-CO-, C1_10 alkyl-0-CO-
NH-, and C1_10 alkyl-S-; 
K is selected from the group consisting of halogen, C1_10 
alkyl, C1_10 perfluoroalkyl, C1_10 alkoxy, N02, CN, OH, 
C02H, amino, C1_10 alkylamino, C2_12 dialkylamino, 40 
C1-C10 acyl, and C1_10 alkoxy-CO-, and C1_10 alkyl-S-; 
The novel class of tripeptide a-ketoamides have the 
following structural formula: 
M 1-AA-AA-AA-CO-NR3R4 
or a pharmaceutically acceptable salt, wherein 
M1 represents H, NH2-CO-, NH2-CS-, NH2-
S02-, X-NH-CO-, X2N-CO-, X-NH-CS-, 
X2N-CS-, X-NH-S02, X2N-S02-, X-CO-, 
X-CS-, X-S02-, X-0-CO-, or X-0-CS-; 
X is selected from the group consisting of C1_10 alkyl, 
c!-10 fluoroalkyl, cl-10 alkyl substituted with J, cl-10 
fluoroalkyl substituted with J, 1-admantyl, 9-f!uorenyl, phe-
nyl, phenyl substituted with K, phenyl disubstituted with K, 
phenyl trisubstituted with K, naphthyl, naphthyl substituted 
with K, naphthyl disubstituted with K, naphthyl trisubsti-
tuted with K, C1_10 alkyl with an attached phenyl group, 
cl-10 alkyl with two attached phenyl groups, cl-10 alkyl 
with an attached phenyl group substituted with K, C1_10 
alkyl with two attached phenyl groups substituted with K, 
cl-10 alkyl with an attached phenoxy group, and cl-10 alkyl 
with an attached phenoxy group substituted with K on the 
phenoxy group; 
J is selected from the group consisting of halogen, COOH, 
OH, CN, N02, NH2, C1_10 alkoxy, C1_10 alkylamine, C2_12 
dialkylamine, C1_10 alkyl-0-CO-, C1_10 alkyl-0-CO-
NH-, and C1_10 alkyl-S-; 
AA1 is a side chain blocked or unblocked amino acid with 
the L configuration, D configuration, or no chirality at the 
a-carbon selected from the . group consisting of alanine, 
valine, leucine, isoleucine, proline, methionine, methionine 45 
sulfoxide, phenylalanine, tryptophan, serine, threonine, cys-
teine, tyrosine, asparagine, glutamine, aspartic acid, 
glutamic acid, lysine, arginine, histidine, phenylglycine, 
beta-alanine, norleucine, norvaline, alpha-aminobutyric 
acid, epsilon-aminocaproic acid, citrulline, hydroxyproline, 50 
ornithine, homoarginine, sarcosine, indoline 2-carboxylic 
acid, 2-azetidinecarboxylic acid, pipecolinic acid (2-piperi-
dine carboxylic acid), 0-methylserine, 0-ethylserine, S-me-
thylcysteine, S-ethylcysteine, S-benzylcysteine, NH2-
CH(CH2CH2)-COOH, alpha-aminoheptanoic acid, NH2- 55 
CH(CH2-l-napthyl)-COOH, NH2-CH(CH2-2-napthyl)-
COOH, NH2-CH(CH2-cyclohexyl)-COOH, NH2-
CH(CH2-cyclopentyl)-COOH, NH2-CH(CH2-cyclobutyl)-
COOH, NH2-CH(CH2-cyclopropyl)-COOH, 
trifluoroleucine, and hexafiuoroleucine; 
AA2 is a side chain blocked or unblocked amino acid with 
the L configuration, D configuration, or no chirality at the 
a-carbon selected from the group consisting of alanine, 
valine, leucine, isoleucine, proline, methionine, methionine 
sulfoxide, phenylalanine, tryptophan, glycine, serine, threo- 65 
nine, cysteine, tyrosine, asparagine, glutamine, aspartic acid, 
glutamic acid, lysine, arginine, histidine, phenylglycine, 
K is selected from the group Consisting of halogen, C1_10 
alkyl, C1_10 perfluoroalkyl, C1_10 alkoxy, N02, CN, OH, 
60 C02H, amino, C1_10 alkylamino, C2_12 dialkylamino, 
C1-C10 acyl, and C1_10 alkoxy-CO-, and C1_10 alkyl-S-; 
AA is a side chain blocked or unblocked amino acid with 
the L configuration, D configuration, or no chirality at the 
a-carbon selected from the group consisting of alanine, 
valine, leucine, isoleucine, proline, methionine, methionine 
sulfoxide, phenylalanine, tryptophan, glycine, serine, threo-
nine, cysteine, tyrosine, asparagine, glutamine, aspartic acid, 
5,610,297 
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glutamic acid, lysine, argmme, histidine, phenylglycine, 
beta-alanine, norleucine, norvaline, alpha-aminobutyric 
acid, epsilon-aminocaproic acid, citrulline, hydroxyproline, 
omithine, homoarginine, sarcosine, indoline 2-carboxylic 
acid, 2-azetidinecarboxylic acid, pipecolinic acid (2-piperi- 5 
dine carboxylic acid), 0-methylserine, 0-ethylserine, S-me-
thylcysteine, S-ethylcysteine, S-benzylcysteine, NH2-
CH(CH2CHet2)-COOH, alpha-aminoheptanoic acid, 
NH2-CH(CH2-l-napthyl)-COOH, NH2-CH(CHr2-
napthyl)-COOH, NH2-CH(CHrcyclohexyl)-COOH, 
NH2-CH(CH2-cyclopentyl)-COOH, NH2-CH(CH2-cy- IO 
clobutyl)-COOH, NH2-CH(CH2-cyclopropyl)-COOH, tri-
fluoroleucine, and hexaftuoroleucine; 
R3 and R4 are selected independently from the group 
consisting of H, C1_20 alkyl, C3_20 cyclized alkyl, C1_20 
alkyl with a phenyl group attached to the cl-20 alkyl, c3-20 15 
cyclized alkyl with an attached phenyl group, cl-20 alkyl 
with an attached phenyl group substituted with K, C1_20 
alkyl with an attached phenyl group disubstituted with K, 
cl-20 alkyl with an attached phenyl group trisubstituted with 
K, C3_20 cyclized alkyl with an attached phenyl group 20 
substituted with K, C1_10 alkyl with a morpholine 
[-N(CH2CH2)0] ring attached through nitrogen to the 
alkyl, cl-10 alkyl with a piperidine ring attached through 
nitrogen to the alkyl, cl-10 alkyl with a pyrrolidine ring 
attached through nitrogen to the alkyl, cl-20 alkyl with an 25 
OH group attached to the alkyl, -CH2CH20CH2CH20H, 
cl-10 with an attached 4-pyridyl group, cl-10 with an 
attached 3-pyridyl group, cl-10 with an attached 2-pyridyl 
group, C1_10 with an attached cyclohexyl group, -NH-
CH2CH2-(4-hydroxyphenyl), and -NH-CH2CH2-(3-in- 3o 
dolyl). 
The novel class of tetrapeptide a-ketoamides have the 
following structural formula: 
M 1-AA-AA-AA-AA-CO-NR3R4 
or a pharmaceutically acceptable salt, wherein 
M1 represents H, NH2-CO-, NH2-CS-, NH2-S02, 
X-NH-CO-, X2N-CO-, X-NH-CS-, X2N-
35 
CS-, X-NH-S02-, X2N-S02-, X-CO-, 40 
X-CS-, X-S02-, X-0-CO-, or X-0-CS-; 
X is selected from the group consisting of C1_10 alkyl, 
cl-10 ftuoroalkyl, cl-10 alkyl substituted with J, cl-10 
ftuoroalkyl substituted with J, 1-admantyl, 9-ftuorenyl, phe-
nyl, phenyl substituted with K, phenyl disubstituted with K, 45 
phenyl trisubstituted with K, naphthyl, naphthyl substituted 
with K, naphthyl disubstituted with K, naphthyl trisubsti-
tuted with K, C1_10 alkyl with an attached phenyl group, 
cl-10 alkyl with two attached phenyl groups, cl-10 alkyl 
with an attached phenyl group substituted with K, C1_10 50 
alkyl with two attached phenyl groups substituted with K, 
cl-10 alkyl with an attached phenoxy group, and cl-10 alkyl 
with an attached phenoxy group substituted with K on the 
phenoxy group; 
J is selected from the group consisting of halogen, COOH, 55 
OH, CN, N02, NH2, C1_10 alkoxy, C1_10 alkylamine, C2_12 
dialkylamine, c 1_10 alkyl-O-CO-, c 1_10 alkyl-O-CO-
NH-, and C1_10 alkyl-S-; 
K is selected from the group consisting of halogen, C1_ 10 
alkyl, C1_10 perfluoroalkyl, C1_10 alkoxy, N02, CN, OH, 60 
C02H, amino, C1_10 alkylamino, C2_12 dialkylamino, 
Ci-C10 acyl, and C1_10 alkoxy-CO-, and C1_10 alkyl-S-; 
10 
nine, cysteine, tyrosine, asparagine, glutamine, aspartic acid, 
glutamic acid, lysine, arginine, histidine, phenylglycine, 
beta-alanine, norleucine, norvaline, alpha-aminobutyric 
acid, epsilon-aminocaproic acid, citrulline, hydroxyproline, 
ornithine, homoarginine, sarcosine, indoline 2-carboxylic 
acid, 2-azetidinecarboxylic acid, pipecolinic acid (2-piperi-
dine carboxylic acid), 0-methylserine, 0-ethylserine, S-me-
thylcysteine, S-ethylcysteine, S-benzylcysteine, NH2-
CH(CH2CHEt2)-COOH, alpha-aminoheptanoic acid, 
NH2-CH(CH2-l-napthyl)-COOH, NH2-CH(CHr2-
napthyl)-COOH, NH2-CH(CH2-cyclohexyl)-COOH, 
NH2-CH(CH2-cyclopentyl)-COOH, NH2-CH(CH2-cy-
clobutyl)-COOH, NH2-CH(CH2-cyclopropyl)-COOH, tri-
ftuoroleucine, and hexaftuoroleucine; 
R3 and R4 are selected independently from the group 
consisting of H, C1_20 alkyl, C3_20 cyclized alkyl, C1_20 
alkyl with a phenyl group attached to the C1_20 alkyl, C3_20 
cyclized alkyl with an attached phenyl group, cl-20 alkyl 
with an attached phenyl group substituted with K, C1_20 
alkyl with an attached phenyl group disubstituted with K, 
cl-20 alkyl with an attached phenyl group trisubstituted with 
K, C3_20 cyclized alkyl with an attached phenyl group 
substituted with K, C1_10 alkyl with a morpholine 
[-N(CH2CH2)0] ring attached through nitrogen to the 
alkyl, cl-10 alkyl with a piperidine ring attached through 
nitrogen to the alkyl, cl-10 alkyl with a pyrrolidine ring 
attached through nitrogen to the alkyl, cl-20 alkyl with an 
OH group attached to the alkyl, -CH2CH20CH2CH20H, 
cl-10 with an attached 4-pyridyl group, cl-10 with an 
attached 3-pyridyl group, cl-10 with an attached 2-pyridyl 
group, C1_10 with an attached cyclohexyl group, -NH-
CH2CH2-( 4-hydroxyphenyl), and -NH-CH2CH2-(3-in-
dolyl). 
The novel class of amino acid a-ketoamides have the 
following structural formula: 
or a pharmaceutically acceptable salt, wherein 
M1 represents H, NH2-CO-, NH2-CS-, NH2-
S02-, X-NH-CO-, X2N-CO-, X-NH-CS-, 
X2N-CS-, X-NH-S02-, X2N-S02-, X-CO-, 
X-CS-, X-S02-, X-0-CO-, or X-0-CS-; 
X is selected from the group consisting of C1_10 alkyl, 
cl-10 ftuoroalkyl, cl-10 alkyl substituted with J, cl-10 
ftuoroalkyl substituted with J, 1-admantyl, 9-ftuorenyl, phe-
nyl, phenyl substituted with K, phenyl disubstituted with K, 
phenyl trisubstituted with K, naphthyl, naphthyl substituted 
with K, naphthyl disubstituted with K, naphthyl trisubsti-
tuted with K, C1_10 alkyl with an attached phenyl group, 
cl-10 alkyl with two attached phenyl groups, cl-10 alkyl 
with an attached phenyl group substituted with K, C1_10 
alkyl with two attached phenyl groups substituted with K, 
cl-10 alkyl with an attached phenoxy group, and cl-10 alkyl 
with an attached phenoxy group substituted with K on the 
phenoxy group; 
J is selected from the group consisting of halogen, COOH, 
OH, CN, N02, NH2, C1_10 alkoxy, C1_10 alkylamine, C2_12 
dialkylamine, C1_10 alkyl-0-CO-, C1_10 alkyl-0-CO-
NH-, and C1_10 alkyl-S-; 
K is selected from the group consisting of halogen, C1_10 
alkyl, C1_10 perftuoroalkyl, C1_10 alkoxy, N02, CN, OH, 
C02H, amino, C1_10 alkylamino, C2_12 dialkylamino, 
Ci-C10 acyl, and C1_10 alkoxy-CO-, and C1_10 alkyl-S-; 
AA is a side chain blocked or unblocked amino acid with 
AA is a side chain blocked or unblocked amino acid with 
the L configuration, D configuration, or no chirality at the 
a-carbon selected from the group consisting of alanine, 
valine, leucine, isoleucine, praline, methionine, methionine 
sulfoxide, phenylalanine, tryptophan, glycine, serine, threo-
65 the L configuration, D configuration, or no chirality at the 
a-carbon selected from the group consisting of alanine, 
valine, leucine, isoleucine, praline, methionine, methionine 
5,610,297 
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sulfoxide, phenylalanine, tryptophan, glycine, serine, threo-
nine, cysteine, tyrosine, asparagine, glutamine, aspartic acid, 
glutamic acid, lysine, arginine, histidine, phenylglycine, 
beta-alanine, norleucine, norvaline, alpha-aminobutyric 
acid, epsilon-aminocaproic acid, citrulline, hydroxyproline, 5 
omithine, homoarginine, sarcosine, indoline 2-carboxylic 
acid, 2-azetidinecarboxylic acid, pipecolinic acid (2-piperi-
dine carboxylic acid), 0-methylserine, 0-ethylserine, S-me-
thylcysteine, S-ethylcysteine, S-benzylcysteine, NH2- 10 CH(CH2CHEtz)-COOH, alpha-aminoheptanoic acid, 
NH2-CH(CH2-l-napthyl)-COOH, NH2-CH(CH2-2-
napthyl)-COOH, NH2-CH(CH2-cyclohexyl)-COOH, 
NH2-CH(CH2-cyclopentyl)-COOH, NH2-CH(CH2-cy-
clobutyl)-COOH, NH2-CH(CHz-cyclopropyl)-COOH, tri- 15 
fluoroleucine, and hexafluoroleucine; 
R3 and R4 are selected independently from the group 
consisting of H, C1_20 alkyl, C3_20 cyclized alkyl, C1_ 20 
alkyl with a phenyl group attached to the cl-20 alkyl, c3-20 
20 
cyclized alkyl with an attached phenyl group, cl-20 alkyl 
with an attached phenyl group substituted with K, C1_ 20 
alkyl with an attached phenyl group disubstituted with K, 
cl-20 alkyl with an attached phenyl group trisubstituted with 
K, C3_20 cyclized alkyl with an attached phenyl group 25 
substituted with K, C1_ 10 alkyl with a morpholine 
[-N(CH2CH2)0] ring attached through nitrogen to the 
alkyl, c!-10 alkyl with a piperidine ring attached through 
nitrogen to the alkyl, cl-10 alkyl with a pyrrolidine ring 
30 attached through nitrogen to the alkyl, cl-20 alkyl with an 
OH group attached to the alkyl, -CH2CH20CH2CH20H, 
c!-10 with an attached 4-pyridyl group, cl-10 with an 
attached 3-pyridyl group, cl-10 with an attached 2-pyridyl 
group, C1_ 10 with an attached cyclohexyl group, -NH- 35 
CH2CHz-(4-hydroxyphenyl), and -NH-CH2CHr(3-in-
dolyl). 
The following compounds are representatives of the 
invention: 
Z-Leu-Phe-CONH-Et 40 
12 
Assay of Inhibitory Potency. Peptide a-ketoamides were 
assayed as reversible enzyme inhibitors. Various concentra-
tions of inhibitors in Me2SO were added to the assay mixture 
which contained buffer and substrate. The reaction was 
started by the addition of the enzyme and the hydrolysis 
rates were followed spectrophotometrically or fluorimetri-
cally. 
Calpain I from human erythrocytes and calpain II from 
rabbit were assayed using Suc-Leu-Tyr-AMC [Sasaki et al., 
J. Biol. Chem. 259, 12489-12494 (1984); incorporated 
herein by reference], and the AMC (7-amino-4-methylcou-
marin) release was followed fiuorimetrically (excitation at 
380 nm, and emmision at 460 nm). Calpains were assayed 
in 25 mM Tris pH=8.0, 10 mM CaC12 . Fluorescence was 
followed using a Gilson FL- IA fluorometer or a Perkin-
Elmer 203 Fluorescence spectrometer. Cathepsin B was 
assayed in 20 mM sodium acetate pH=5.2, 0.5 mM dithio-
threitol using Bz-Phe-Val-Arg-p-nitroanilide as substrate. 
Alternately, cathepsin B was assayed with Z-Arg-Arg-AFC 
[Barrett and Kirschke, Methods Enzymol. 80, 535-561 
(1981); incorporated herein by reference], and the AFC 
(7-amino-4-trifiuoromethylcoumarin) release was followed 
fluorimetrically (excitation at 400 nm and emmision at 505 
nm). Papain was assayed in 100 mM KP04 , I mM EDTA, 
2.5 mM cysteine pH=6.0 using Bz-Arg-AMC or Bz-Arg-NA 
[Kanaoka et al., Chem. Plmrrn. Bull. 25, 3126-3128 (1977); 
incorporated herein by reference] as a substrate. The AMC 
(7-amino-4-methylcoumarin) release was followed fluori-
metrically (excitation at 380 run, and emmision at 460 nm). 
Enzymatic hydrolysis rates were measured at various sub-
strate and inhibitor concentrations, and K1 values were 
determined by either Lineweaver-Burk plots or Dixon plots. 
AO. IM Hepes, 0.5M NaCl, pH 7.5 buffer was utilized for 
human leukocyte elastase (HLE), porcine pancreatic elastase 
(PPE), chymotrypsin and cathepsin G. A 0.1 Hepes, O.OIM 
CaC12, pH 7.5 buffer was utilized for trypsin, plasmin, and 
coagulation enzymes. A 50 mM Tris-HCl, 2 mM EDTA, 5 
mM cysteine, pH 7.5 was used as a buffer for papain. A 88 
mM KH2P04 , 12 mM Na2HP04 , 1.33 mM EDTA, 2.7 mM 
Z-Leu-Phe-CONH-nPr 
Z-Leu-Phe-CONH-nBu 
Z-Leu-Phe-CONH-iBu 
Z-Leu-Phe-CONH-Bzl 
Z-Leu-Phe-CONH-(CH2 ) 2Ph 
Z-Leu-Abu-CONH-Et 
Z-Leu-Abu-CONH-nPr 
Z-Leu-Abu-CONH-nBu 
Z-Leu-Abu-CONH-iBu 
Z-Leu-Abu-CONH-Bzl 
Z-Leu-Abu-CONH-(CH2)zPh 
Z-Leu-Abu-CONH-(CH2h-N(CH2CH2)z0 
Z-Leu-Abu-CONH-(CH2hCH3 
Z-Leu-Abu-CONH-(CH2)z0H 
Z-Leu-Abu-CONH-(CH2)zO(CH2)zOH 
Z-Leu-Abu-CONH-(CH2 ) 17CH3 
Z-Leu-Abu-CONH-CH2--C6H3(0CH3)z 
Z-Leu-Abu-CONH-CH2--C4H4N 
45 cysteine, pH 6.0 solution was used as a buffer for cathepsin 
B. A 20 mM Hepes, 10 mM CaC12 , 10 mM mercatoethanol, 
pH 7.2 buffer was utilized for calpain I and calpain II. 
Materials and Methods. HEPES, heparin, and A23187 
were obtained from Calbiochem. Suc-Leu-Tyr-AMC and 
chromogenic substrates were obtained from Sigma. Calpain 
I was purified from human erythrocytes according to the 
method of Kitahara (Kitahara et al., J. Biochem. 95, 
1759-1766) omitting the Blue-Sepharose step. Calpain II 
from rabbit muscle and cathepsin B were purchased from 
Sigma. Papain was purchased from Calbiochem. 
HLE and PPE were assayed with MeO-Suc-Ala-Ala-Pro-
Val-NA and Sue-Ala-Ala-Ala-NA, respectively [Nakajima 
50 
et al., J. Biol. Chem. 254, 4027-4032 (1979); incorporated 
herein by reference]. Human leukocyte cathepsin G and 
chymotrypsin A"" were assayed with Suc-Val-Pro-Phe-NA 
[Tanaka et al., Biochemistry 24, 2040-2047 (1985); incor-
55 porated herein by reference]. The hydrolysis of peptide 
4-nitroanilides was measured at 410 nm [ e410=8800 M-1cm-
1; Erlanger et al., Arch. Biochem. Biophys. 95, pp 271-278 
(1961); incorporated herein by reference]. Trypsin, throm-
bin, human plasma kallikrein, porcine pancreatic kallikrein, 
60 human factor Xia, and human plasmin were assayed with 
Z-Arg-SBzl or Z-Gly-Arg-SBu-i [McRae et al., Biochem-
istry 20, 7196-7206 (1981); incorporated herein by refer-
ence]. All peptide thioester hydrolysis rates were measured 
65 with assay mixtures containing 4,4'-dithiodipyridine [e324= 
19800 M-1cm-1; Grasetti & Murray, Arch. Biochem. Bio-
phys. 119, 41-49 (1967); incorporated herein by reference]. 
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the Biorad AP conjugate substrate kit. Quantitative densito-
metry was used to obtain values for the intact spectrin bands 
and the 1501155 kDa breakdown product doublet. 
Structure-Activity Relationships. Table I shows the inhi-
bition constants (K1) for cathepsin B, calpain I, and calpain 
II. Dipeptide a-ketoamides with Abu and Phe in the P 1 site 
and Leu in the P2 site are potent inhibitors of calpain I and 
calpain I/. Z-Leu-Abu-CONH-Et is a better inhibitor of 
Platelet membrane permeability assay. Calpain-mediated 
breakdown of spectrin was measured by quantitative densi-
tometry of the calpain-specific 1501155 kDa spectrin frag-
ment doublet [see Siman et al., Proc. Natl. Acad. Sci. USA 
81, 3572-3576 (1984)]. Platelets were isolated by a modi- 5 
fication of the method of Ferrell and Martin [J. Biol. Chem. 
264, 20723-20729 (1989)]. Blood (15-20 ml) was drawn 
from male Sprague-Dawley rats into 1/10th volume of 100 
mM EDTA-citrate, and centrifuged 10 minutes at 2000 rpm 10 calpain I than Z-Leu-Phe-CONH-Et by 14 fold. Replace-
ment of the Z group (PhCH20CO-) by similar groups such 
as PhCH2CH2CO-, PhCH2CH2S02-, PhCH2NHCO-, 
and PhCH2NHCS- would also result in good inhibitor 
in a clinical centrifuge at room temperature. The plasma was 
resuspended in 15 ml of buffer 1 (136 mM NaCl, 2.7 mM 
KC!, 0.42 mM NaH2P04 , 12 mM NaHC03 , 2 mM MgC12, 
2 mg/ml BSA (Sigma), 5.6 mM glucose, 22 mM Na3 citrate 
pH 6.5) and platelets were isolated at 2200 rpm at room 
temperature for 10 minutes. Platelets were washed once in 
15 ml buffer 1, then resuspended to 107 cells/ml in buffer 2 
(136 mM NaCl, 2.7 mM KCl, 0.42 mM NaH2P04 , 12 mM 
NaHC03, 2mM MgCl, 1 mg/ml BSA (Sigma), 5.6 mM 
glucose, 20 mM HEPES (Sigma) pH 7.4) and allowed to 
"rest" for a minimum of 10 minutes at room temperature 
before use. 
15 structures. The best inhibitor of calpain II is Z-Leu-Abu-
CONH-(CH2)2-Ph. Changing the R3 and R4 groups sig-
nificantly improves the inhibitory potency toward calpain II. 
The best di peptide inhibitors are those which have long alkyl 
side chains (e.g. Z-Leu-Abu-CONH-(CH2hCH3 ), alkyl 20 
Inhibitors were added from stock solutions made fresh in 
DMSO. 100 µI platelets, suspended to 107 cells/ml in buffer 25 
2, were incubated with 1 µI of an inhibitor solution for 5 
minutes at room temperature prior to the addition of 2 mM 
Ca2+ and 1 uM A23 187. After 10 minutes total exposure to 
inhibitor (5 minutes exposure to ionophore) at room tem-
perature, platelets were reisolated at 14,000 rpm for 10 sec 
side chains with phenyl substituted on the alkyl group (e.g. 
Z-Leu-Abu-CONH-(CH2)z-Ph), or alkyl groups with a 
morpholine ring substituted on the alkyl group [e.g. Z-Leu-
Abu-CONH-(CH2h)-Mpl, Mpl=--N(CH2CH2)zO]. 
Dipeptide a-ketoamides with a small aliphatic amino acid 
residue or a Phe in the P 1 site are also good inhibitors for 
cathepsin B. The best inhibitor is Z-Leu-Abu-CONH-Et and 
replacement of the Z (PhCH20CO-) by PhCH2CH2CO-, 
PhCH2CH2S02-, PhCH2NHCO-, and PhCH2NHCS-
would also result in good inhibitor structures. 
TABLE 1 
Inhibition of Cysteine Proteases by Peptide a-Ketoamides. 
Peptide a-Ketoamide Calpain I Calpain II CathB 
Z-Leu-Abu-CONH-Et 
Z-Leu-Abu-CONH-nPr 
Z-Leu-Abu-CONH-nBu 
Z-Leu-Abu-CONH-iBu 
Z-Leu-Abu-CONH-Bzl 
Z-Leu-Abu-CONH-(CH2),-Ph 
Z-Leu-Abu-CONH-(CH,)3-Mpl 
Z-Leu-Abu-CONH-(CH,)7CH3 
Z-Leu-Abu-CONH-(CH,)17CH, 
Z-Leu-Abu-CONH-(CH,)20H 
Z-Leu-Abu-CONH-(CH,)20(CH2 ),0H 
Z-Leu-Phe-CONH-Et 
Z-Leu-Phe-CONH-nPr 
Z-Leu-Phe-CONH-nBu 
Z-Leu-Phe-CONH-iBu 
Z-Leu-Phe-CONH-Bzl 
Z-Leu-Phe-CONH(CH2),Ph 
0.5 
0.2 
0.16 
7.0 
15.0 
0.23 
0.25 
0.14 
0.35 
0.022 
0.041 
0.019 
O.D78 
0.32 
0.05 
0.028 
0.065 
0.046 
0.024 
2.4 
8 
13 
4 
2 
6 
3 
3 
4 
in a Beckman microfuge, dissolved in SDS-PAGE sample 55 
buffer, and heated to 90° C. for 3 minutes. 
Samples were subjected to SDS-PAGE in 4-12% gradient 
mini gels (Novex) and transferred to nitrocellulose (Schle-
icher and Schnell 0.45 um) by electroblotting. Filters were 
60 blocked for 10 minutes in 0.25% gelatin, 1 % BSA, 0.25% 
triton XIOO, 0.9% NaCl, 10 mM Tris-Cl pH 7.5, incubated 
overnight in the same solution containing antibody to rat 
spectrin, washed 3x10 minutes with 10 mM Tris-Cl pH 7.5, 
0.5% triton XlOO, incubated 4 hours in wash buffer plus 65 
alkaline phosphatase conjugated goat anti-rabbit antibody 
(Biorad), and washed as above. Blots were developed using 
Table II shows the inhibition constants (K1) for PP elastase 
and chymotrypsin. Dipeptide a-ketoamides with Abu in the 
P 1 site are potent inhibitors of PP elastase. The structures 
with medium sized straight-chain alkyl groups such as n-Pr 
and n-Bu were better inhibitors than a small alkyl (Et) or a 
branched alkyl (i-Bu). Dipeptide a-ketoamides with Phe in 
the P 1 site are moderate inhibitors of chymotrypsin. The 
inhibitor with R3=n-Bu and R4=H was the best in the series. 
In general the inhibitors were more potent at inhibiting 
cysteine protease than serine proteases. Extending the pep-
tide chain to tripeptide or tetrapeptide a-ketoamides would 
improve the inhibitory potency toward serine proteases. 
15 
TABLE II 
Inhibition of Serine Proteases by Peptide a-Ketoamides. 
Peptide a-Ketoamide 
Z-Leu-Abu-CONH-Et 
Z-Leu-Abu-CONH-nPr 
Z-Leu-Abu-CONH-nBu 
Z-Leu-Abu-CONH-iBu 
Z-Leu-Abu-CONH-Bzl 
Z-Leu-Abu-CONH-(CH2),-Ph 
Z-Leu-Abu-CONH-(CH2),-Mpl 
Z-Leu-Abu-CONH-(CH2),CH3 
Z-Leu-Abu-CONH-(CH2)17CH3 
Z-Leu-Abu-CONH-(CH2),0H 
Z-Leu-Abu-CONH-(CH2),0(CH2),0H 
Z-Leu-Phe-CONH-Et 
Z-Leu-Phe-CONH-nPr 
Z-Leu-Phe-CONH-nBu 
Z-Leu-Phe-CONH-iBu 
Z-Leu-Phe-CONH-Bzl 
Z-Leu-Phe-CONH(CH2),Ph 
Chymo-
trypsin 
>150 
>300 
>300 
>300 
>300 
73 
18 
8 
24 
5,610,297 
PP 
elas-
tase 
65 
2 
5 
40 
>150 
>300 
10 
15 
>100 20 
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TABLE III-continued 
Half-lives in Plasma and in Liver and 
Activity in the Platelet Assay. 
Peptide a-Ketoamide or Ester platelet 
Z-Leu-Abu-CONH-nPr 70 
Z-Leu-Abu-CONH-nBu 2.0 
Z-Leu-Abu-CONH-iBu 28 
Z-Leu-Abu-CONH-Bzl 1.5 
Z-Leu-Phe-COOEt 42 
Z-Leu-Phe-COOnBu +++ 
Z-Leu-Phe-COOBz ++ 
Z-Leu-Leu-Phe-COOEt ++ 
Z-Leu-Phe-COOH 6.5 
Z-Leu-Phe-CONH-Et 1.7 
Z-Leu-Phe-CONH-nPr 24 
Z-Leu-Phe-CONH-nBu 38 
Z-Leu-Phe-CONH-iBu 22 
Z-Leu-Phe-CONH-Bzl 
Z-Leu-Phe-CONH(CH2),Ph 3.0 
Z-Leu-Nle-COOEt 20 
Z-Leu-Nva-COOEt 40 
Z-Leu-Met-COOEt + 
t112 
plasma 
>60 
>60 
>60 
>60 
7.8 
7.7 
1.9 
>60 
>60 
>60 
>60 
>60 
>60 
3.7 
2.8 
8 
1112 
liver 
>60 
>60 
>60 
>60 
>60 
>60 
>60 
( +++ = excellent activity; 
++ = good activity, 
25 + = moderate activity; quantitative measurements not yet complete) Peptide a-ketoamide were substantially more stable in 
both plasma and liver than the corresponding peptide a-ke-
toesters (Table III). The peptide a-ketoamides were also 
much more effective in the platelet assay. Extending the R3 
group to an alkyl group or an alkyl group substituted with a 
phenyl group increased the membrane permeability of the 30 
inhibitors as indicated by increased potency in the platelet 
Inhibition Mechanism. A crystal structure of one a-ke-
toester bound into the active site of porcine pancreatic 
elastase has been completed and a schematic drawing of the 
interactions observed is shown below. The active site Ser-
195 oxygen of the enzyme has added to the carbonyl group 
of the ketoester to form a tetrahedral intermediate which is assay. 
TABLE III 
Half-lives in Plasma and in Liver and 
Activity in the Platelet Assay. 
Peptide a-Ketoamide or Ester platelet 
Z-Leu-Abu-COOEt 42 
Z-Leu-Abu-COOn-Bu 28 
Z-Leu-Abu-COOBzl ++ 
Z-Leu-Leu-Abu-COOEt 40 
2-NapS02-Leu-Leu-Abu-COOEt 100 
2-NapCO-Leu-Leu-Abu-COOEt 
Tos-Leu-Leu-Abu-COOEt 30 
Z-Leu-Abu-COOH 8 
Z-Leu-Abu-CONH-Et 1.5 
t112 
plasma 
2.8 
>60 
25 
30 
>60 
>60 
tl/2 
liver 
>60 
>60 
stabilized by interactions with the oxyanion hole. This 
structure resembles the tetrahedral intermediate involved in 
35 peptide bond hydrolysis and proves that a-ketoesters are 
40 
45 
transition-state analogs. His-57 is hydrogen bonded to the 
carbonyl group of the ester functional group, the peptide 
backbone on a section of PPE's backbone hydrogen bonds 
to the inhibitor to form a ~-sheet, and the benzyl ester is 
directed toward the S' subsites. The side chain of the P 1 
amino acid residue is located in the S 1 pocket of the enzyme. 
Interactions with ketoamides would be similar except for 
that there would be the possibility of forming an additional 
hydrogen bond with the NH group of the ketoamide func-
tional group if R3 or R4 was H. If R3 and/or R4 are longer 
substutuents, then they would make favorable interactions 
with the S' subsites of the enzyme. 
n s~ Ill /~-195 0 
~o ~~)-Ko~ l( I ,o,- o, 
0 H I \ \ 
: , ~ ,H 
S' subsites 
\ 
N~ 
~N'-H 
Val-216 
H b oxyanion 
I ll hole 
/Nlf~ 
0 Ser-214 
His-57 
Phe-214 
5,610,297 
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The active site of cysteine proteases share several features 
in common with serine proteases including an active site 
histidine residue. In place of the Ser-195, cysteine proteases 
have an active site cysteine residue which would add to the 
ketonic carbonyl group of the peptide keto acids, keto esters, 5 
or ketoamides to form an adduct very similar to the structure 
depicted above except with a cysteine residue replacing the 
serine- 195 residue. Additional interactions would occur 
between the extended substrate binding site of the cysteine 
protease and the inhibitor which would increase the binding 10 
affinity and specificity of the inhibitors. 
Inhibitor Design and Selection. The peptide and amino 
acid a-ketoamide derivatives, as shown in the above crystal 
structure, bind to the enzymes using many of the interactions 
that are found in complexes of a particular individual 15 
enzyme with its substrates. In order to design an inhibitor for 
a particular serine or cysteine protease, it is necessary to: I) 
find the amino acid sequences of good peptide substrates for 
that enzyme, and 2) place those or similar amino acid 
sequences into a a-ketoamide structure. Additional interac- 20 
tions with the enzyme can be obtained by tailoring the R 
group of the inhibitor to imitate the amino acid residues 
which are preferred by an individual protease at the S1' and 
S2' subsites. For example, ketoesters with R3 and/or 
R4=branched alkyl groups would interact effectively with 25 
serine and cysteine proteases which prefer Leu, Ile, and Val 
Z-Gly-Leu-Phe-CO-NR3R4 
Me0-Suc-Ala-Ala-Pro-Met-CO-NR3R4 
Boc-Ala-Ala-Asp-CO-NR3R. 
18 
cysteine proteases based on knowledge of their substrate 
specificities. Once a good inhibitor structure for a particular 
enzyme is found, it is then possible to change other char-
acteristics such as solubility or hydrophobicity by adding 
substituents to the M 1 or R3 and R4 groups. 
Elastase is an enzyme which hyrolyzes most effectively 
tetra- and tripeptides having P 1 residues with small alkyl 
side chains such as Ala and Val. MeO-Suc-Ala-Ala-Ala-Val-
NA and Z-Ala-Ala-Ala-Ala-NA are good substrates (NA= 
4-nitroanilide). Thus the corresponding a-ketoamide Z-Ala-
Al a-Ala-DL-Ala-CO-NR3R4 and Me0-Suc-Ala-Ala-Pro-
DL-Abu-CO-NR3R4 will be excellent elastase inhibitors. 
Suc-Phe-Leu-Phe-NA is an excellent substrate for chymot-
rypsin, cathepsin G, and mast cell chymases. Thus, the 
corresponding a-ketoamide will be an excellent inhibitor for 
these chymotrypsin-like enzymes. In the case of the cysteine 
protease calpain, a good inhibitor sequence is Ac-Leu-Leu-
Nle-H. We have found that ketoesters related in structure 
such as Z-Leu-Abu-CO-NR3R4 and Z-Leu-Phe-CO-
NR3R4 are potent inhibitors for calpain. 
The following structures are predicted to be potent inhibi-
tors for the listed enzymes. The inhibitor sequences were 
obtained from peptide substrate and/or inhibitor sequences 
in the protease literature. 
for cathepsin G and RMCP II 
for cathepsin G 
for human lymphocyte granzyme B 
Suc-Pro-Leu-Phe-CO-NR3R4 and Boc-Ala-Ala-Phe-CO-NR3R4 
Boc-Gly-Leu-Phe-CO-NR3R,, Suc-Phe-Leu-Phe---CO-NR3R4 
Boc-Ala-Ala-Glu-CO-NR3R4 
for RMCP I (RMCP =rat mast cell protease) 
for human and dog skin chymase 
for S. aureus V-8 protease 
Z-Gly-Gly-Pro-CO-NR3R4 
Ala-Pro-CO-NR3R4 
Suc-Ala-Ala-Pro-Val-CO-NR3R4 
Suc-Lys(Cbz)-Val-Pro-Val-CO-NR3R4, adamantyl-
S02-Lys(COCH2CH2C02H)-Ala-Val-CO-NR3R4, 
adamantyl-CH2CH20CO-Glu(O-t-Bu-Pro-Val-CO-NR3R4, 
and adamantyl-S02-Lys(CO-C6H4C02H)-Ala-Val-CO-NR3R4 
Suc-Ala-Ala-Pro-Leu-CO-NR3R4 
for human prolyl endopeptidase 
for DPP IV 
for PPE 
for human leukocyte (neutrophil) elastase 
Glu-Phe-Lys-CO-NR3R4 and Dns-Ala-Phe-Lys-CO-NR3R4 
D-Val-Gly-Arg-CO-NR3R, and Dns-Glu-Gly-Arg-CO-NR3R4 
Z-Phe-Arg-CO-NR3R4 and Z-Trp-Arg-CO-NR3R4 
Z-Lys-Arg-CO-NR3R4 
for elastolytic proteinase from "Schistosoma mansoni" 
for plasmin 
for factor Xa 
for porcine pancreatic and human plasma kallikreins 
for human skin tryptase 
Z-Gly-Arg-CO-NR3R4 
Z-Ile-Ala-Gly-Arg-CO-NR3R, 
Glu-Gly-Arg-CO-NR3R4 
Dns-Phe-Pro-Arg-CO-NR3R, 
Dns-Ile-Pro-Arg-CO-NR3R, 
Z-Trp-Arg-CO-NR3R4 
Z-Gly-Arg-CO-NR3R4 
Z-Phe-Arg-CO-NR3R4 
Dns-Glu-Gly-Arg-CO-NR3R, 
for human lung tryptase 
for factors IXa, Xa, Xla, Xlla and bovine plasma 
kallikrein 
for urokinase 
for plasminogen activator 
for activated protein C 
for bovine factor IXa 
for bovine factor Xa and Xla 
for bovine factor XIIa 
for human factor Xa 
D-Phe-Pro-Arg-CO-NR3R4, D-MePhe-Pro-Arg-CO-NR3R4, and 
Boc-D-Phe-Pro-Arg-CO-NR3R, 
for human thrombin 
Z-Phe-Gly-Arg-CO-NR,R4 
Cl-C6H4CH20CO-Phe-G!y-CO-NR3R, 
c.H5CH2NHCO-Gly-Phe-Gly-CO-NR3R4 
residues at P 1' and/or P2', while amides with R=alkyl sub-
stituted with phenyl would interact effectively with serine 
and cysteine proteases which prefer Phe, Tyr, Trp residues at 
P1' and/or P2'. Likewise, the M1 group can be tailored to 
interact with the S subsites of the enzyme. This design 
strategy will also work when other classes of peptide inhibi-
tors are used in place of the peptide substrate to gain 
information on the appropriate sequence to place in the 
ketoester, ketoacid, or ketoamide inhibitor. Thus, we are able 
to predict the structure of new inhibitors for other serine and 
for trypsin 
for papain 
for cathepsin B 
R3 and R4 are selected independently from the group 
consisting of H, C1_20 alkyl, C3_20 cyclized alkyl, C1_20 
60 alkyl with a phenyl group attached to the cl-20 alkyl, c3-20 
cyclized alkyl with an attached phenyl group, cl-20 alkyl 
with an attached phenyl group substituted with K, C1_20 
alkyl with an attached phenyl group disubstituted with K, 
cl-20 alkyl with an attached phenyl group trisubstituted with 
65 K, C3_20 cyclized alkyl with an attached phenyl group 
substituted with K, C1_ 10 alkyl with a morpholine 
[-N(CH2CH2)0] ring attached through nitrogen to the 
5,610,297 
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alkyl, C1_JO alkyl with a piperidine ring attached through 
nitrogen to the alkyl, cl-JO alkyl with a pyrrolidine ring 
attached through nitrogen to the alkyl cl-20 alkyl with an 
OH group attached to the alkyl, -CH2CH20CH2CH20H, 
cl-10 with an attached 4-pyridyl group, cl-JO with an 
attached 3-pyridyl group, cl-JO with an attached 2-pyridyl 
group, C1_JO with an attached cyclohexyl group, -NH-
CH2CHz-(4-hydroxyphenyl), and -NH-CH2CHz-(3-in-
dolyl). 
In Vitro Uses. To use the above inhibitors in vitro, they are 
dissolved in an organic solvent such as dimethylsulfoxide or 
ethanol, and are added to an aqueous solution containing 
serine and/or cysteine proteases. The final concentration of 
the organic solvent should be less than 25%. The inhibitors 
may also be added as solids or in suspension. The serine and 
cysteine protease inhibitors of this invention would be useful 
in a variety of experimental procedures where proteolysis is 
a significant problem. Inclusion of these inhibitors in a 
radioimmunoassay experiments would result in higher sen-
sitivity. The use of these inhibitors in plasma fractionation 
procedures would result in higher fields of valuable plasma 
proteins and would make purification of the proteins easier. 
The inhibitors disclosed here could be used in cloning 
experiments utilizing bacterial cultures, yeast and human 
cells to yield a purified cloned product in higher yield. 
The novel compounds of this invention are effective in the 
prevention of unnecessary proteolysis caused by chymot-
rypsin-like and elastase-like enzymes in the process of 
purification, transport and storage of peptides and proteins 
as shown in Table II by effective inhibition of chymotrypsin 
and elastase and other cysteine proteases. 
In Vivo Uses. Effective inhibitors of the proteolytic func-
tion of human leukocyte elastase and chymotrypsin-like 
enzymes (Table II) would have anti-inflammatory activity 
and can be used to treat and control emphysema, adult 
respiratory distress syndrome and rheumatoid arthritis. 
Effective inhibitors of the proteolytic function of chymot-
rypsin and pancreatic elastase (Table II) are effective for 
theraputic use in the treatment of pancreatitis. 
Peptide a-ketoamide can be used to control protein turn-
over, muscular dystrophy, myocardial tissue damage, tumor 
metastasis, and bone resorption as shown in Table I by 
effective inhibition of lysosomal cathepsin B in buffer. 
Peptide a-ketoamides can also be used as neuroprotectants 
or for the treatment of ischemia, stroke or Alzheimer's 
disease as shown in Table I by effective inhibiton of calpain 
I and calpain II. 
Considerable evidence has shown that leukocyte elastase 
and/or related enzymes play a role in tumor cell metastasis 
[Salo et al., Int. J. Cancer 30, pp 669-673 (1973); Kao et al., 
Biochem. Biophys. Res. Comm. 105, pp 383-389 (1982); 
Powers, J. C. in Modification of Proteins, R. E. Feeney and 
20 
incorporated herein by reference]. Leukocyte elastase and 
other mediators of inflammation also appear to play a role in 
diseases such as mucocutaneous lymph node syndrome 
[Reiger et al., Eur. J. Pediatr. 140, 92-97 (1983); incorpo-
5 rated herein by reference] and adult respiratory distress 
syndrome [Stockley, Clinical Science 64, 119-126 (1983); 
Lee et al., N. Eng. J. Med. 304, 192-196 (1981); Rinaldo, 
ibid 301, 900-909 (1982); incorporated herein by reference]. 
It is known that in vitro activity of elastase inhibitors 
10 
correlates with in vivo activity in animal models of emphy-
sema and inflammation [Ottemess et al., editors, Advances 
in Intimation Research, Vol. 11, Raven Press 1986; incor-
porated herein by reference]. Prophylactic administration of 
an inhibitor of elastase significantly diminishes the extent of 
elastase-induced emphysema [Kleinerman et al., Am. Rev. 
15 Resir. Dis. 121, 381-387 (1980); Lucey et al., Eur. Respir. 
J. 2, 421--427 (1989); incorporated herein by reference]. 
Thus the novel inhibitors described here should be useful for 
the treatment of emphysema and inflammation. Elastase 
inhibitors have been used orally, by injection, or by instil-
20 lation in the lungs in animal studies (Powers, Am. Rev. 
25 
Respir. Dis., 127, s54-s58 (1983); Powers and Bengali, Am. 
Rev. Respir. Dis. 134, 1097-1100 (1986); these two articles 
are incorporated herein by reference). The inhibitors 
described above can be used by any of these routes. 
Drug Delivery. For therapeutic use, the peptide a-ketoa-
mides may be administered orally, topically or parenterally. 
The term parenteral as used includes subcutaneous injection, 
intravenous, intramuscular, intrastemal injection or infusion 
techniques. The dosage depends primarily on the specific 
formulation and on the object of the therapy or prophylaxis. 
30 The mount of the individual doses as well as the adminis-
tration is best determined by individually assessing the 
particular case. 
The pharmaceutical compositions containing the active 
ingredient may be in a form suitable for oral use, for 
35 example as tablets, troches, lozenges, aqueous or oily sus-
pensions, dispersible powders or granules, emulsions, hard 
or soft capsules or syrups or elixirs. Dosage levels of the 
order to 0.2 mg to 140 mg per kilogram of body weight per 
day are useful in the treatment of above-indicated conditions 
40 (10 mg to 7 gms per patient per day). The amount of active 
ingredient that may be combined with carrier materials to 
produce a single dosage form will vary depending upon the 
host treated and the particular mode of administration. 
For injection, the therapeutic amount of the peptide a-ke-
45 toarnides or their pharmaceutically acceptable salts will 
normally be in the dosage range from 0.2 to 140 mg/kg of 
body weight. Administration is made by intravenous, intra-
muscular or subscutaneous injection. Accordingly, pharma-
ceutical compositions for parenteral administration will con-
tain in a single dosage form about 10 mg to 7 gms of the 
50 compounds per dose. In addition to the active ingredient, 
these pharmaceutical compositions will usually contain a 
buffer, e.g. a phosphate buffer which keeps the pH in the 
range from 3.5 to 7 and also sodium chloride, mannitol or J. R. Whitaker, eds., Adv. Chem. Ser 198,Amer. Chem. Soc., 
Wash., D.C. pp 347-367 (1982); all incorporated herein by 
reference], therefore it is suggested that compounds of this 55 
invention may have anti-tumor activity. 
sorbitol for adjusting the isotonic pressure. 
A composition for topical application can be formulated 
as an aqueous solution, lotion, jelly or an oily solution or 
suspention. A composition in the form of an aqueous solu-
tion is obtained by dissolving the compounds of this inven-
tion in aqueous buffer solution of pH 4 to 6.5 and if desired, 
Pulmonary emphysema is a disease characterized by 
progressive loss of lung elasticity due to the destruction of 
lung elastin and alveoli. The destructive changes of lung 
parentchyma associated with pulmonary emphysema are 
caused by uncontrolled proteolysis in lung tissues [Janoff, 
Chest 83, 54-58 (1983); incorporated herein by reference]. 
60 adding a polymeric binder. An oily formulation for topical 
application is obtained by suspending the compounds of this 
invention in an oil, optionally with the addition of a swelling 
agent such as aluminum stearate and/or a surfactant. A number of proteases have been shown to induce emphy-
sema in animals [Marco et al., Am. Rev. Respir. Dis. 104, 
595-598 (1971); Kaplan, J. Lab. Clin. Med. 82, 349-356 65 
(1973); incorporated herein by reference], particularly 
human leukocyte elastase [Janoff, ibid 115, 461--478 (1977); 
SYNTHETIC METHODS 
The a-ketoamide inhibitors are prepared from the corre-
sponding a-ketoamide. The ketoester inhibitors are prepared 
5,610,297 
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by a two step Dakin-West from the corresponding peptide 
acid (Charles et al., J. Chem. Soc. Perkin 1, 1139-1146, 
1980). This procedure can be utilized with either amino acid 
derivatives, dipeptide derivatives, tripeptidc derivatives, or 
tetrapeptide derivatives as shown in the following scheme. 5 
M1-AA-OH~Enol Ester~M1-AA-CO-O-R 
22 
dipeptides, tripeptides, and tetrapeptides M1-AA-AA-OH, 
M1-AA-AA-AA-OH, or M1-AA-AA-AA-AA-OH which 
could be be used in the Dakin-West reaction. The substituted 
peptides Mi-AA-AA-OH, M1 -AA-AA-AA-OH, or M 1-AA-
AA-AA-AA-OH could also be prepared directly from 
H-AA-AA-OH, H-AA-AA-AA-OH, or H-AA-AA-AA-AA-
OH using the reactions described above for introduction of 
the M1 group. Alternately, the M1 group could be introduced 
by reaction with carboxyl blocked peptides to give M1-AA-M1-AA-AA-OH~Enol Ester~M 1-AA-AA-CO-O-R 
M1-AA-AA-AA-OH~Enol Ester~M,-AA-AA-AA-C0-0-R 
10 AA-OR', Mi-AA-AA-AA-OR', or M1-AA-AA-AA-AA-
OR', followed by the removal of the blocking group R'. 
M 1-AA-AA-AA-AA-OH~Enol Ester~M 1-AA-AA-AA-AA­
C0-0-R 
The precursor peptide can be prepared using standard 
peptide chemistry which is well described in publications 
such as The Peptides, Analysis, Synthesis, Biology, Vol. 1-9, 
published in 1979-1987 by Academic Press and Houben-
Weyl Methoden der Organischen Chemie, Vol. 15, Parts 1 
and 2, Synthese von Peptiden, published by Georg Thieme 
Verlag, Stuttgart in 1974 (both references incorporated 
herein by reference). 
The R group in the ketoester structures is introduced 
during the Dakin-West reaction by reaction with an oxalyl 
chloride Cl-CO-C0-0-R. For example, reaction of 
M1-AA-AA-OH with ethyl oxalyl chloride Cl-CO-C0-
15 0-Et gives the keto ester M1-AA-AA-CO-O-Et. Reaction 
of Mi-AA-AA-AA-AA-OH with Cl-CO-C0-0-Bzl 
would give the ketoester Mi-AA-AA-AA-AA-C0-0-Bzl. 
Clearly a wide variety ofR groups can be introduced into the 
ketoester structure by reaction with various alkyl or aryla-
20 lkyl oxalyl chlorides (C1-CO-CO-O-R). The oxalyl 
chlorides are easily prepared by reaction of an alkyl or 
arylalkyl alcohol with oxalyl chloride Cl-CO-CO-Cl. 
For example, Bzl-0-CO-CO-Cl and n-Bu-0-CO-
CO-Cl are prepared by reaction of respectively benzyl 
The M1 group can be introduced using a number of 
different reaction schemes. First it could be introduced 
directly on an amino acid as shown in the following scheme 
(top), or the M1 group could be introduced by reaction with 
an amino acid ester, followed by removal of the ester group 
to give the same product (bottom). 
25 alcohol and butanol with oxalyl chloride in yields of 50% 
and 80% [Warren, C. B., and Malee, E. J., J. Chromatog-
raphy 64, 219-222 (1972); incorporated herein by refer-
ence]. 
H-AA-OH~M,-AA-OH 
M1-AA-O R'~M1-AA-O-R'~M1-AA-OH 
The techniques for introduction of the M1 group is well 
documented in the The Peptides, Houben-Weyel, and many 
other textbooks on organic synthesis. For example reaction 
with cyanate or p-nitrophenyl cyanate would introduce a 
carbamyl group (M1=NH2CO-). Reaction with 
Me2NCOC1 would introduce the Me2NCO- group. Reac-
tion with p-nitrophenyl thiocarbamate would introduce a 
thio carbamyl group (M1=NH2CS-). Reaction with 
NH2S02Cl would introduce the NH2S02- group. Reaction 
with Me2NS02Cl would introduce the Me2NS02- group. 
Reaction with a substituted alkyl or aryl isocyanate would 
introduce the X-NH-CO- group where X is a substi-
tuted alkyl or aryl group. Reaction with a substituted alkyl 45 
or aryl isothiocyanate would introduce the X-NH-CS-
group where Xis a substututed alkyl or aryl group. Reaction 
with X-S02-Cl would introduce the X-S02- group. 
Reaction with a substituted alkyl or aryl acid chloride would 
introduce an acyl group (M=X-CO-). For example, reac- 50 
tion with Me0-CO-CH2CH2-CO-Cl would give the 
X-CO- group where Xis a C2 alkyl substituted with a C1 
alkyl-OCO- group. Reaction with a substituted alkyl or 
aryl thioacid chloride would introduce a thioacyl group 
(M=X-CS-). Reaction with an a substituted alkyl or aryl 55 
sulfonyl chloride would introduce an X-S02- group. For 
example reaction with dansyl chloride would give the 
X-S02- derivative where X was a naphthyl group mono 
substituted with a dimethylamino group. Reaction with a 
substituted alkyl or aryl chloroformate would introduce a 60 
X-0-CO- group. Reaction with a substituted alkyl or 
aryl chlorothioformate would introduce a X-0-CS-. 
There are many alternate reaction schemes which could be 
used to introduce all of the above M1 groups to give either 
Mi-AA-OH or Mi-AA-OR'. 
Ketoamides M1-AA-CO-NR3R4, M-AA-AA-C0-
3o NR3R4, M-AA-AA-AA-CO-NR3R4, M-AA-AA-AA-AA-
CO-NR3R4 were prepared indirectly from the ketoesters. 
The ketone carbonyl group was first protected as shown in 
the following scheme and then the ketoamide was prepared 
by reaction with an amine H-NR3R4. The illustrated pro-
35 cedure should also work with other protecting groups. In 
addition, the corresponding ketoacid could be used as a 
precursor. Blocking the ketone carbonyl group of the 
ketoacid and then coupling with an amine H-NR3R4 using 
standard peptide coupling reagents would yield an interme-
The M1 -AA-OH derivatives could then be used directly in 
the Dakin-West reaction or could be converted into the 
40 diate which could then be deblocked to form the ketoamide. 
65 
/\ 
M1-AA2/~~0'-R 
R1 0 
~H-NR3Ri 
0 RJ 
~. )l k 
M1-AA2/ l TI '-&i 
R1 0 
The following detailed examples are given to illustrate the 
invention and are not intended to limit it in any manner. 
EXAMPLE 1 
Z-Leu-Phe-CONH-Et 
To a stirred solution of Z-Leu-Phe-OH (20 g, 48.5 
mmole), 4-dimethylaminopyridine (0.587 g, 4.8 mmole),and 
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pyridine (15.7 ml, 194 mmole) in anhydrous THF (100 ml) 
was added ethyl oxalyl chloride (11.4 ml, 101.8 mmole) at 
a rate sufficient to initiate refluxing. The mixture was gently 
refluxed for 4 hours, cooled to room temperature, and water 
(80 ml) was added. The reaction mixture was stirred vigor- 5 
ously for 30 rain, and extracted with ethyl acetate (3xl00 
ml). The combined organic layers were washed with water 
(2xl00 ml), saturated sodium chloride (2xl00 ml), decol-
orized with decolorizing carbon, dried over magnesium 
sulfate, and concentrated, leaving a dark orange oil. Chro-
10 
matography on a silica gel column with CHC13/CH30H 
(50:1 v/v) afforded 14.63 g (y=53%) of Z-Leu-Phe-eno-
lester. The product was a yellow oil. Single spot on TLC, 
R.t=0.77 (CHCliCH30H 50:1). NMR (CDC13 ) ok. 
To a stirred pale yellow solution of the Z-Leu-Phe-
enolester (14.63 g, 25.73 mmole) in anhydrous ethanol (50 15 
ml) was added a solution of sodium ethoxide (0.177 g, 2.6 
mmole) in ethanol (5 ml). The orange solution was stirred 
for 3 hours at room temperature, then the ethanol was 
evaporated and the residue was treated with ethyl ether (300 
ml). The ether layer was washed with water (2xl00 ml), 20 
saturated sodium chloride (2xl00 ml), dried over magne-
sium sulfate, and concentrated, leaving a orange oil. Chro-
matography on a silica gel column with CHC13/CH30H (50:1 v/v) afforded 7.76 g (y=64%) of the a-ketoester 
Z-Leu-Phe-COOEt. The product was a yellow oil. Single 25 
spot on TLC, R.t=0.44 (CHCliCH30H 50: 1). NMR (CDC13 ) 
ok. MS (FAB, calcd. for C26H32N20 6 : 468.6), m/e=469 (M+l). 
24 
described in Example 1. Single spot on TLC, 
R.t=0.50.(CHCliCH30H 50:1); mp 152°-153° C. Anal. 
calcd. for C28H37N30 5 : 495.59; C, 67.85; H, 7.52; N, 8.48. 
Found: C, 67.70; H, 7.57; N, 8.43. NMR (CDC13 ) ok. MS 
(FAB) m/e=496 (M+l). 
EXAMPLE4 
Z-Leu-Phe-CONH-iBu 
This compound was synthesized from the protected a-ke-
toester and isobutylamine in 53% yield by the procedure 
described in Example 1. Single spot on TLC, R_t=0.54 
(CHC13/CH30H 50:1); mp 152° C. Anal. calcd. for 
C28H37N30 5 : 495.59; C, 67.85; H, 7.52; N, 8.48. Found: C, 
67.77; H, 7.56; N, 8.40. NMR (CDC13 ) ok. MS (FAB) 
m/e=496 (M+l). 
EXAMPLE 5 
Z-Leu-Phe-CONH-Bzl 
This compound was synthesized from the protected a-ke-
toester and benzylamine in 40% yield by the procedure 
described in Example I. After reacting overnight, ethyl 
acetate (60 ml) was added. The mixture was filtered to 
remove a white precipitate. The solution was washed with 
cooled lN HCl (3x25 ml), water (lx20 ml), saturated 
sodium chloride (2x20 ml), and dried over magnesium 
sulfate. The solution was evaporated leaving a yellow solid. The a-carbonyl group of Z-Leu-Phe-COOEt was pro-
tected by the following procedure. To a solution of Z-Leu-
Phe-COOEt ( 1 g, 2.13 mmole) in 5 ml of CH2Cl2 was added 
1,2-ethanedithiol (0.214 ml, 2.55 mmole), followed by 0.5 
ml of boron trifluoride etherate. The solution was stirred 
overnight at room temperature. Water (20 ml) and ethyl ether 
(20 ml) were added. The organic layer was separated, 
washed with water (2x10 ml), saturated sodium chloride 
(2x10 ml), dried over magnesium sulfate, and evaporated to 
afford 0.98 g (y=84%) yellow semisolid. 
30 Chromatography on a silica gel column with CHCliCH30H 
30:1 v/v) afforded a yellow solid. Single spot on TLC, 
R.t=0.45 (CHCliCH30H 30:1); mp 160°-162° C. Anal. 
calcd. for C31H35N30 5 : 529.61; C, 70.30; H, 6.66; N, 7.93. 
Found: C, 70.18; H, 6.67; N, 7.99. NMR (CDC13) ok. MS 
35 (FAB) m/e=530 (M+l). 
The protected a-ketoester (0.98 g, 1.8 mmole) was dis-
solved in ethanol (5 ml), cooled to 0°-5° C. in an ice bath, 40 
and ethylamine was bubbled through the solution until 2.43 
g (54 mmole) had been added. The reaction mixture was 
allowed to warm to room temperature slowly, and stirred 
overnight. The mixture was filtered, a white precipitate was 
removed, leaving a yellow semisolid. Chromatography on a 45 
silica gel column with CHC13/CH30H (30: 1 v/v) afford 0.63 
g (y=75%) ofZ-Leu-Phe-CONH-Et. The product was a pale 
yellow solid. Single spot on TLC, R.t=0.60 (CHC13/CH30H 
20:1); mp 145°-147° C. Anal. calcd. for C26H33N30 5 : 
467.56; C, 66.79; H 7.11; N,8.99; found: C, 66.59; H, 7.09; 50 
N, 8.95. NMR (CDC13 ) ok. MS (FAB) m/e=468 (M+l). 
EXAMPLE 2 
Z-Leu-Phe-CONH-nPr 
EXAMPLE 6 
Z-Leu-Phe-CONH-(CH2)zPh 
This compound was synthesized from the protected a-ke-
toester and phenethylamine in 50% yield by the procedure 
described in Example 5. Single spot on TLC, R.t=0.50 
(CHCliCH30H 30:1); mp 151°-153° C. Anal. calcd. for 
C32H37N30 5 : 543.66; C, 70.70; H, 6.86; N, 7.73. Found: C, 
70.54; H, 6.88; N, 7.74. NMR (CDC13 ) ok. MS (FAB) 
m/e=544 (M+l). 
EXAMPLE? 
Z-Leu-Abu-CONH-Et 
This compound was synthesized from protected a-ke-
toester derived from Z-Leu-Abu-C02Et and ethylamine in 
64% yield by the procedure described in Example I. Single 
55 spot on TLC, R.t=0.36 (CHCliCH30H 50;1); mp 130°-132° C. Anal. calcd. for C21H31N30 5 : 405.45; C, 62.20; H, 7.71; 
N, 10.36. Found: C, 61.92; H, 7.62; N, 10.31. NMR (CDC13) 
ok. MS (FAB) m/e=406 (M+l). 
This compound was synthesized from the protected a-ke-
toester and propylamine in 92% yield by the procedure 
described in Example I. Single spot on TLC, R.t=0.50 
(CHCliCH30H 50:1); mp 152°-153° C. Anal. calcd. for 
C27H35N30 5 : 481.57; C, 67.33; H, 7.33; N, 8.72. Found: C, 60 67.21; H, 7.38; N, 8.64. NMR (CDC13 ) ok. MS (FAB) 
m/e=482 (M+l). 
EXAMPLE3 
Z-Leu-Phe-CONH-nBu 
This compound was synthesized from the protected a-ke-
toester and butylamine in 67% yield by the procedure 
EXAMPLE 8 
Z-Leu-Abu-CONH-nPr 
This compound was synthesized from the corresponding 
protected a-ketoester and propylamine in 47% yield by the 
65 procedure described in Example 1. Single spot on TLC, 
R.t=0.28 (CHCl/CH30H 50:1); mp 134°-135° C. Anal. 
calcd. for C22H33N30 5 : 419.50; C, 62.98; H, 7.93; N, 10.02. 
5,610,297 
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Found: C, 62.84; H, 7.97; N, 9.94. NMR (CDC13) ok. MS 
(FAB) m/e=420 (M+l). 
EXAMPLE 9 
Z-Leu-Abu-CONH-nBu 
5 
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EXAMPLE 14 
Z-Leu-Abu-CONH-(CH2hCH3 
This compound was synthesized from the corresponding 
protected a-ketoester and octylamine in 67% yield by the 
procedure described in Example 5. It was white solid. Single 
spot on TLC, R.t=0.55 (CHC13'CH30H 30: l); mp 134 °-135° 
C. Anal. calcd. for C27H43N30 5 : 489.66; C, 66.23; H, 8.85; 
This compound was synthesized from the corresponding 
protected a-ketoester and butylamine in 42% yield by the 
procedure described in Example 1. Single spot on TLC, 
R.t=0.54 (CHC13'CH30H 50:1); mp 135°-136° C. Anal. 
calcd. forC23H35N30 5 : 433.53; C, 63.71; H N, 9.69. Found: 
10 N, 8.58. Found: C, 66.19; H, 8.81; N, 8.61. NMR (CDC13 ) 
ok. MS (FAB) m/e=490 (M+l). 
C, 63.48; H, 8.07; N, 9.67. NMR·(CDC13) ok. MS (FAB) 
m/e=434 (M+l). 
EXAMPLE 10 
Z-Leu-Abu-CONH-iBu 
15 
EXAMPLE 15 
Z-Leu-Abu-CONH-(CH2)zOH 
This compound was synthesized from the corresponding 
protected a-ketoester and ethanolamine in 29% yield by the This compound was synthesized from the corresponding 
protected a-ketoester and isobutylamine in 65% yield by the 
procedure described in Example 1. Single spot on TLC, 
R.t=0.25 (CHC13'CH30H 50:1); mp 133°-135° C. Anal. 
calcd. for C23H35N30 5 : 433.52; C, 63.72; H, 8.14; N, 9.69. 
Found: C, 63.46; H, 8.10; N, 9.60. NMR (CDC13 ) ok. MS 
(FAB) m/e=434 (M+l). 
20 procedure described in Example 13. The product was a 
white sticky solid. Single spot on TLC, R_r=0.42 (CHC13' 
CH30H 10:1); mp 151°-153° C. Anal: calcd. for 
C21 H31N30 6 : 421.49; C, 59.84; H, 7.41; N, 9.97. Found: C, 
59.11; H, 7.44; N, 9.81. NMR (CDC13 ) ok. MS (FAB) 
25 m/e=422 (M+l). 
EXAMPLE 11 
Z-Leu-Abu-CONH-Bzl 
This compound was synthesized from the corresponding 30 
protected a-ketoester and benzylamine in 29% yield by the 
procedure described in Example 5. Single spot on TLC, 
R_FD.56 (CHC13/CH30H 30:1); mp 140°-141° C. Anal. 
calcd. for C26H33N30 5 : 467.54; C, 66.79; H 7.11; N, 8.99. 
Found: C, 66.65; H, 7.07; N, 8.93. NMR (CDC13 ) ok. MS 35 
(FAB) m/e=468 (M+l). 
EXAMPLE 12 
Z-Leu-Abu-CONH-(CH2)zPh 
This compound was synthesized from the corresponding 
protected a-ketoester and phenethylamine in 51 % yield by 
40 
the procedure described in Example 5. Single spot on TLC, 
R_r=0.44 (CHC13/CH30H 30:1); mp 156°-157° C. Anal. 45 
calcd. for C27H35N30 5 : 481.59; C, 67.34; H, 7.33; N, 8.72. 
Found: C, 67.38; H, 7.33; N, 8.78. NMR (CDC13) ok. MS 
(FAB) m/e=482 (M+l). 
EXAMPLE 16 
Z-Leu-Abu-CONH-(CHz)20(CHz)20H 
This compound was synthesized from the corresponding 
protected a-ketoester and 2-(2-aminoethoxy)ethanol in 34% 
yield by the procedure described in Example 13. The prod-
uct was white sticky solid. Single spot on TLC, R_r=0.42 
(CHC13'CH30H 10:1); mp 103°-105° C. Anal.: calcd. for 
C23H35N30 7 : 465.55; C, 59.34; H, 7.58; N, 9.03. Found: C, 
59.23; H, 7.58; N, 9.01. NMR (CDC13) ok. MS (FAB) 
m/e=466 (M+l). 
EXAMPLE 17 
Z-Leu-Abu-CONH-(CH2 ) 17CH3 
This compound was synthesized from the corresponding 
protected a-ketoester and octadecylamine in 12% yield by 
the procedure described in Example 5. The product was a 
pale yellow solid. Single spot on TLC, R_r=0.54 (CHC13' EXAMPLE 13 
50 CH30H 30:1); mp 134°-136° C. Anal: calcd. for 
C37H63N30 5 : 629.92; C, 70.55; H, 10.08; N, 6.67. Found: C, 
70.71; H, 10.14; N, 6.75. NMR (CDC13 ) ok. MS (FAB) 
m/e=630.2 (M+l). This compound was synthesized from protected a-ke-
toester and 4(3-aminopropyl)morpholine in 33% yield by 
the procedure described in Example 1. After reacting over- 55 
night, ethyl acetate (80 ml) was added. The mixture was 
filtered to remove a white precipitate. The solution was 
washed with water (3x20 ml), saturated sodium chloride 
(2x20 ml), and dried over magnesium sulfate. The solution 
was evaporated leaving a yellow oil. Chromatography on a 60 
silica gel column. with CHC13'CH30H (10:1 v/v) afforded a 
yellow semisolid, which was recrystallized from ethyl 
acetate/hexane to obtain a pale yellow solid. Single spot on 
TLC, R_r=0.42 (CHC13'CH30H 10:1); mp 125°-126° C. 
Anal. calcd. for C26H~406: 504.63; C, 61.88; H, 7.99; N, 65 
11.10. Found; C, 61,69; H, 7.95; N, 11.07. NMR (CDC13) 
ok. MS (FAB) m/e=505 (M+l). 
EXAMPLE 18 
Z-Leu-Abu-CONH-CH2-C6H3(0CH3)z 
This compound was synthesized from the corresponding 
protected a-ketoester and 3,5-dimethoxybenzylamine in 
45% yield by the procedure described in Example 5. The 
product was yellow sticky solid. Single spot on TLC, 
R_r=0.44 (CHC13/CH30H 30:1); mp 153°-155° C. Anal.: 
calcd. for C28H37N30 7 : 527.62; C, 63.74; H, 7.07; N, 7.96. 
Found: C, 63.66; H, 7.09; N, 7.92. NMR (CDC13) ok. MS 
(FAB) m/e=528.8 (M+l). 
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EXAMPLE 19 
Z-Leu-Abu-CONH-CH2-C4H4N 
This compound was synthesized from the corresponding 5 
protected a-ketoester and 4-(aminomethyl)pyridine in 45% 
yield by the procedure described in Example 13. The prod-
uct was greenish yellow solid. Single spot on TLC, R;=0.55 
(CHCl/CH30H 10:1); mp 124°-126° C. Anal: calcd. for 
C25H32N4 0 5: 468.55; C, 64.08; H, 6.88; N, 11.96. Found: C, 10 
63.88; H, 6.87; N, 11.96. NMR (CDCl3) ok. MS (FAB) 
m/e=469 (M+l). 
It is obvious that those skilled in the art may make 
modifications to the invention without departing from the 
spirit of the invention or the scope of the subjoined claims 15 
and their equivalents. 
What is claimed is: 
1. A peptide ketoamide compound of the formula: 
M 1-AA2-AARES-CO-NH-R4 
or a pharmaceutically acceptable salt, wherein 
AARES represents AA1' 
20 
M1 represents H, NH2-CO-, NH2-CS-, NH2-
S02-, X-NH-CO-, X2N-CO-, X-NH- 25 
CS-, X2N-CS-, X-NH-S02-, X2N-S02-, 
X-CO-, X-CS-, X-S02-, X-0-CO-, or 
X-0-CS-; 
X is selected from the group consisting of C1_10 alkyl, 
cl-10 fiuoroalkyl, c!-10 alkyl substituted with J, cl-10 30 
fiuoroalkyl substituted with J, 1-admantyl, 9-fiuorenyl, 
phenyl, phenyl substituted with K, phenyl disubstituted 
with K, phenyl trisubstituted with K, naphthyl, naph-
thyl substituted with K, naphthyl disubstituted with K, 
naphthyl trisubstituted with K, C1_10 alkyl with an 35 
attached phenyl group, c!-10 alkyl with two attached 
phenyl groups, c!-10 alkyl with an attached phenyl 
group substituted with K, C1_10 alkyl with two attached 
phenyl groups substituted with K, C1_10 alkyl with an 
attached phenoxy group, and cl-10 alkyl with an 40 
attached phenoxy group substituted with K on the 
phenoxy group; 
J is selected from the group consisting of halogen, COOH, 
OH, CN, N02, NH2, C1_10 alkoxy, C1_10 alkylamine, 45 C2_12 dialkylamine, C1_10 alkyl-0-CO-, C1_10 
alkyl-0-CO-NH-, and C1_10 alkyl-S-; 
K is selected from the group consisting of halogen, C1_10 
alkyl, C1_10 perfiuoroalkyl, C1_10 alkoxy, N02, CN, 
OH, C02H, amino, C1_10 alkylamino, C2_12 dialky- 50 
!amino, CcC10 acyl, C1_10 alkoxy-CO-, and C1_10 
alkyl-S-; 
AA2 is a side chain blocked or unblocked amino acid with 
the L configuration, D configuration, or no chirality at 
the a-carbon selected from the group consisting of 55 
alanine, valine, leucine, isoleucine, proline, methion-
ine, methionine sulfoxide, phenylalanine, tryptophan, 
glycine, serine, threonine, cysteine, tyrosine, aspar-
agine, glutarnine, aspartic acid, glutamic acid, lysine, 
arginine, histidine, phenylglycine, beta-alanine, norleu- 60 
cine, norvaline, alpha-aminobutyric acid, epsilon-ami-
nocaproic acid, citrulline, hydroxyproline, ornithine, 
homoarginine, sarcosine, indoline 2-carboxylic acid, 
2-azetidinecarboxylic acid, pipecolinic acid (2-piperi-
dine carboxylic acid), 0-methylserine, 0-ethylserine, 65 
S-methylcysteine, S-ethylcysteine, S-benzylcysteine, 
NH2-CH(CH2CHEt2)-COOH, alpha-aminohep-
28 
tanoic acid, NH2-CH(CHr 1-napthyl)-COOH, 
NH2CH(CH2-2-naphthyl)-COOH, NH2-CH(CH2-cy-
clohexyl)-COOH, NH2-CH(CHrcyclopentyl)-
COOH, NH2-CH(CH2-cyclobutyl)-COOH, NH2-
CH(CH2-cyclopropyl)-COOH, trifiuoroleucine, and 
hexafi uoroleucine; 
AA 1 is a side chain blocked or unblocked amino acid with 
the L configuration, D configuration, or no chirality at 
the a-carbon selected from the group consisting of 
alanine, valine, leucine, isoleucine, proline, methion-
ine, methionine sulfoxide, phenylalanine, tryptophan, 
serine, threonine, cysteine, tyrosine, asparagine, 
glutamine, aspartic acid, glutamic acid, lysine, argin-
ine, histidine, phenylglycine, beta-alanine, norleucine, 
norvaline, alpha-arninobutyric acid, epsilon-aminocap-
roic acid, citrulline, hydroxyproline, omithine, 
homoarginine, sarcosine, indoline 2-carboxylic acid, 
2-azetidinecarboxylic acid, pipecolinic acid (2-piperi-
dine carboxylic acid), 0-methylserine, 0-ethylserine, 
S-methylcysteine, S-ethylcysteine, S-benzylcysteine, 
NH2-CH(CH2CHEti)-COOH, alpha-aminohep-
tanoic acid, NH2-CH(CH2-l-napthyl)-COOH, 
NH2CH(CHr2-napthyl)-COOH, NH2-CH(CH2-cy-
clohexyl)-COOH, NH2-CH(CH2-cyclopentyl)-
COOH, NH2-CH(CH2-cyclobutyl)-COOH, NH2-
CH(CH2-cyclopropyl)-COOH, trifiuoroleucine, and 
hexafiuoroleucine; and 
R4 is selected from the group consisting of C3_20 cyclized 
alkyl with an attached phenyl group, cl-20 alkyl with 
an attached phenyl group substituted with K, C1_20 
alkyl with an attached phenyl group disubstituted with 
K, C1_20 alkyl with an attached phenyl group trisub-
stituted with K, C3_20 cyclized alkyl with an attached 
phenyl group substituted with K, C1_10 alkyl with a 
morpholine ring attached through nitrogen to the alkyl, 
cl-10 alkyl with a piperidine ring attached through 
nitrogen to the alkyl, cl-10 alkyl with a pyrrolidine ring 
attached through nitrogen to the alkyl, cl-20 alkyl with 
an OH group attached to the alkyl, 
-CH2CH20CH2CH20H, C1_10 alkyl with an attached 
4-pyridyl group, cl-10 alkyl with an attached 3-pyridyl 
group, cl-10 alkyl with an attached 2-pyridyl group, 
-NH-CH2CH2-(4-hydroxyphenyl), and -NH-
CH2CH2-(3-indolyl). 
2. A peptide ketoamide compound for inhibiting serine 
and cysteine proteases selected from the group consisting of: 
(a) Z-Leu-Phe-CONH-(CH2)iPh, 
(b) Z-Leu-Abu-CONH-(CH2)iPh, 
(c) Z-Leu-Abu-CONH-(CH2h-N(CH2CH2)20 (mor-
pholino), 
(d) Z-Leu-Abu-CONH-(CH2hCH3, 
(e) Z-Leu-Abu-CONH-(CH2)iOH, 
(f) Z-Leu-Abu-CONH-(CH2)iO(CH2)iOH, 
(g) Z-Leu-Abu-CONH-(CH2)17CH3, 
(h) Z-Leu-Abu-CONH-CH2-C6H3(0CH3)2 (3,5 
dimethoxy); and 
(i) Z-Leu-Abu-CONH-CH2-C4H4N (4-pyridyl). 
3. A peptide ketoamide compound of the formula: 
M1-AA2-AARES-CO-NH-R4 
or a pharmaceutically acceptable salt, wherein 
AARES represents AA1, 
M1 represents H, NH2-CO-, NH2-CS-, NH2-
S02-, X-NH-CO-, X2N-CO-, X-NH-
5,610,297 
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CS-, X2N-CS-, X-NH-S02-, X2N-S02-, 
X-CO-, X-CS-, X-S02-, X-0-CO-, or 
X-0-CS-; 
X is selected from the group consisting of C1_10 alkyl, 
cl-10 ftuoroalkyl, cl-10 alkyl substituted with J, cl-10 5 
ftuoroalkyl substituted with J, 1-admantyl, 9-ftuorenyl, 
phenyl, phenyl substituted with K, phenyl disubstituted 
with K, phenyl trisubstituted with K, naphthyl, naph-
thyl substituted with K, naphthyl disubstituted with K, 
naphthyl trisubstituted with K, C1_10 alkyl with an 10 
attached phenyl group, cl-10 alkyl with two attached 
phenyl groups, cl-10 alkyl with an attached phenyl 
group substituted with K, C1_10 alkyl with two attached 
phenyl groups substituted with K, C1_10 alkyl with an 
attached phenoxy group, and cl-10 alkyl with an 
attached phenoxy group substituted with K on the 15 
phenoxy group; 
J is selected from the group consisting of halogen, COOH, 
OH, CN, N02, NH2, C1_10 alkoxy, C1_10 alkylamine, 
C2_12 dialkylamine, C1_10 alkyl-0-CO-, C1_10 
alkyl-0-CO-NH-, and C1_10 alkyl-S-; 
20 
K is selected from the group consisting of halogen, C1_10 
perftuoroalkyl, C1_10 alkoxy, N02, CN, OH, C02H, 
amino, cl-10 alkylamino, c2-12 dialkylamino, cl-10 
acyl, C1_10 alkoxy-CO-, and C1_10 alkyl-S-; 25 
AA2 is a side chain blocked or unblocked amino acid with 
the L configuration, D configuration, or no chirality at 
the a-carbon selected from the group consisting of 
alanine, valine, leucine, isoleucine, proline, methion-
ine, methionine sulfoxide, phenylalanine, tryptophan, 30 
glycine, serine, threonine, cysteine, tyrosine, aspar-
agine, glutamine, aspartic acid, glutamic acid, lysine, 
arginine, histidine, phenylglycine, beta-alanine, norleu-
cine, norvaline, alpha-aminobutyric acid, epsilon-ami-
nocaproic acid, citrulline, hydroxyproline, ornithine, 35 
homoarginine, sarcosine, indoline 2-carboxylic acid, 
2-azetidinecarboxylic acid, pipecolinic acid (2-piperi-
dine carboxylic acid), 0-methylserine, 0-ethylserine, 
S-methylcysteine, S-ethylcysteine, S-benzylcysteine, 
NH2-CH(CH2CHEt2)-COOH, alpha-aminohep- 40 
tanoic acid, NH2-CH(CH2-l-napthyl)-COOH, 
NH2-CH(CH2-2-naphthyl)-COOH, NH2-CH(CH2-
cyclohexyl)-COOH, NH2-CH(CH2-cyc!opentyl)-
COOH, NH2-CH(CH2-cyclobutyl)-COOH, NH2-
CH(CH2-cyclopropyl)-COOH, triftuoroleucine, and 45 
hexaftuoroleucine; 
AA1 is a side chain blocked or unblocked amino acid with 
the L configuration, D configuration, or no chirality at 
the a-carbon selected from the group consisting of 
alanine, valine, leucine, isoleucine, proline, methion- 50 
ine, methionine sulfoxide, phenylalanine, tryptophan, 
serine, threonine, cysteine, tyrosine, asparagine, 
glutarnine, aspartic acid, glutamic acid, lysine, argin-
ine, histidine, phenylglycine, beta-alanine, norleucine, 
norvaline, alpha-aminobutyric acid, epsilon-aminocap- 55 
roic acid, citrulline, hydroxyproline, ornithine, 
homoarginine, sarcosine, indoline 2-carboxylic acid, 
2-azetidinecarboxylic acid, pipecolinic acid (2-piperi-
dine carboxylic acid), 0-methylserine, 0-ethylserine, 
S-methylcysteine, S-ethylcysteine, S-benzylcysteine, 60 
NH2-CH(CH2CHEt2)-COOH, alpha-arninohep-
tanoic acid, NH2-CH(CH2-l-napthyl)-COOH, 
NH2CH(CH2-2-napthyl)-COOH, NH2-CH(CH2-cy-
clohexyl)-COOH, NH2-CH(CHz-cyclopentyl)-
COOH, NH2-CH(CH2-cyclobutyl)-COOH, NH2- 65 
CH(CH2-cyclopropyl)-COOH, triftuoroleucine, and 
hexaftuoroleucine; and 
30 
R4 is selected from the group consisting of C3 _20 cyclized 
alkyl with an attached phenyl group, C1_20 alkyl with 
an attached phenyl group substituted with K, C1_20 
alkyl with an attached phenyl group disubstituted with 
K, C1_20 alkyl with an attached phenyl group trisub-
stituted with K, C3_20 cyclized alkyl with an attached 
phenyl group substituted with K, C1_10 alkyl with a 
morpholine ring attached through nitrogen to the alkyl, 
cl-10 alkyl with a piperidine ring attached through 
nitrogen to the alkyl, cl-10 alkyl with a pyrrolidine ring 
attached through nitrogen to the alkyl, cl-20 alkyl with 
an OH group attached to the alkyl, 
-CH2CH20CH2CH20H, C1_10 alkyl with an attached 
4-pyridyl group, cl-10 alkyl with an attached 3-pyridyl 
group, cl-10 alkyl with an attached 2-pyridyl group, 
-NH-CH2CH2-(4-hydroxyphenyl), and -NH-
CH2CH2-(3-indolyl). 
4. A peptide ketoamide compound of the formula: 
M1-AA2-AARES-CO-NH-R., 
or a pharmaceutically acceptable salt, wherein 
AARES represents AA1, 
M1 represents H, NH2-CO-, NH2-CS-, NH2-
S02-, X-NH-CO-, X2N-CO-, X-NH-
CS-, X2N-CS-, X-NH-S02-, X2N-S02-, 
X-CO-, X-CS-, X-S02-, X-0-CO-, or 
X-0-CS-; 
X is selected from the group consisting of C1_10 alkyl, 
cl-10 ftuoroalkyl, cl-10 alkyl substituted with J, cl-10 
ftuoroalkyl substituted with J, 1-admantyl, 9-ftuorenyl, 
phenyl, phenyl substituted with K, phenyl disubstituted 
with K, phenyl trisubstituted with K, naphthyl, naph-
thyl substituted with K, naphthyl disubstituted with K, 
naphthyl trisubstituted with K, C1_10 alkyl with an 
attached phenyl group, cl-10 alkyl with two attached 
phenyl groups, cl-10 alkyl with an attached phenyl 
group substituted with K, C1_ 10 alkyl with two attached 
phenyl groups substituted with K, C1_10 alkyl with an 
attached phenoxy group, and cl-10 alkyl with an 
attached phenoxy group substituted with K on the 
phenoxy group; 
J is selected from the group consisting of halogen, COOH, 
OH, CN, N02, NH2, C1_10 alkoxy, C1_10 alkylamine, 
C2_12 dialkylamine, C1_10 alkyl-0-CO-, C1_10 
alkyl-0-CO-NH-, and cl-10 alkyl-S-; 
K is selected from the group consisting of halogen, C1_ 10 
alkyl, C1_10 perftuoroalkyl, C1_10 alkoxy, N02, CN, 
OH, C02H, amino, C1_10 alkylarnino, C2_12 dialky-
lamino, C1-C10 acyl, C1_10 alkoxy-CO-, and C1_10 
alkyl-S-; 
AA2 is a side chain blocked or unblocked amino acid with 
the L configuration, D configuration, or no chirality at 
the a-carbon selected from the group consisting of 
alanine, valine, leucine, isoleucine, proline, methion-
ine, methionine sulfoxide, phenylalanine, tryptophan, 
glycine, serine, threonine, cysteine, tyrosine, aspar-
agine, glutamine, aspartic acid, glutamic acid, lysine, 
arginine, histidine, phenylglycine, beta-alanine, norleu-
cine, norvaline, alpha-aminobutyric acid, epsilon-ami-
nocaproic acid, citrulline, hydroxyproline, omithine, 
homoarginine, sarcosine, indoline 2-carboxylic acid, 
2-azetidinecarboxylic acid, pipecolinic acid (2-piperi-
dine carboxylic acid), 0-methylserine, 0-ethylserine, 
S-methylcysteine, S-ethylcysteine, S-benzylcysteine, 
NH2-CH(CH2CHEtz)-COOH, alpha-aminohep-
tanoic acid, NH2-CH(CH2-l-napthyl)-COOH, 
5,610,297 
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NH2CH(CHz-2-napthyl)-COOH, NH2-CH(CH2-cy-
clohexyl)-COOH, NH2-CH(CH2-cyclopentyl)-
COOH, NH2-CH(CHz-cyclobutyl)-COOH, NH2-
CH(CH2-cyclopropyl)-COOH, trifluoroleucine, and 
hexafluoroleucine; 5 
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CH(CHz-cyclopropyl)-COOH, trifluoroleucine, and 
hexatluoroleucine; and 
R4 is selected from the group consisting of C1_ 10 alkyl 
with a morpholine ring attached through nitrogen to the 
alkyl, cl-10 alkyl with a piperidine ring attached 
through nitrogen to the alkyl, c,_10 alkyl with a pyr-
rolidine ring attached through nitrogen to the alkyl, 
C1_20 alkyl with an OH group attached to the alkyl, 
-CH2CH20CH2CH20H, C1_ 10 alkyl with an attached 
4-pyridyl group, cl-10 alkyl with an attached 3-pyridyl 
group, cl-10 alkyl with an attached 2-pyridyl group, 
-NH-CH2CH2-(4-hydroxyphenyl), and -NH-
CH2CH2-(3-indolyl). 
AA, is a side chain blocked or unblocked amino acid with 
the L configuration, D configuration, or no chirality at 
the a-carbon selected from the group consisting of 
alanine, valine, leucine, isoleucine, proline, methion-
ine, methionine sulfoxide, phenylalanine, tryptophan, 10 
serine, threonine, cysteine, tyrosine, asparagine, 
glutamine, aspartic acid, glutarnic acid, lysine, argin-
ine, histidine, phenylglycine, beta-alanine, norleucine, 
norvaline, alpha-arninobutyric acid, epsilon-aminocap-
roic acid, citrulline, hydroxyproline, ornithine, 
homoarginine, sarcosine, indoline 2-carboxylic acid, 
2-azetidinecarboxylic acid, pipecolinic acid (2-piperi-
dine carboxylic acid), 0-methylserine, 0-ethylserine, 
S-methylcysteine, S-ethylcysteine, S-benzylcysteine, 
5. A peptide ketoamide compound for inhibiting serine 
15 and cysteine proteases selected from the group consisting of: 
NH2-CH(CH2CHEt2)-COOH, alpha-aminohep- 20 
tanoic acid, NH2-CH(CH2-l-napthyl)-COOH, 
NH2-CH(CHz-2-napthyl)-COOH, NH2-CH(CH2-
cyclohexyl)-COOH, NH2-CH(CHz-cyclopentyl)-
COOH, NH2-CH(CHz-cyclobutyl)-COOH, NH2-
(a) Z-Leu-Abu-CONH-(CH2h-
N(CH2CH2h0(morpholino ), 
(b) Z-Leu-Abu-CONH-(CH2)z0H, 
(c) Z-Leu-Abu-CONH-(CH2)z0(CH2)20H, 
(d) Z-Leu-Abu-CONH-CH2-C6H3(0CH3 ) 2, and 
(e) Z-Leu-Abu-CONH-CH2-C4H4N (2-pyridyl). 
* * * * * 
